[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 229
6. Klosterman E, Colitz CM, Chandler HL, Kusewitt DF, Saville WJ, Dubielzig RR: Immunohistochemical properties of ocular adenomas, adenocarcinomas and medulloepitheliomas. Vet Ophthalmol; 2006 Nov-Dec;9(6):387-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical properties of ocular adenomas, adenocarcinomas and medulloepitheliomas.
  • Ocular medulloepitheliomas, adenomas and adenocarcinomas share a common phenotype and originate from the optic cup neuroectoderm.
  • CK20 immunostaining was found in the adenomas but not in the adenocarcinomas or medulloepitheliomas.
  • AE1/AE3 expression was present more consistently in the adenocarcinomas and less frequently in the adenomas.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / immunology. Adenocarcinoma / veterinary. Adenoma / diagnosis. Adenoma / immunology. Adenoma / veterinary. Animals. Dogs. Female. Immunohistochemistry / veterinary. Male. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / immunology. Neuroectodermal Tumors, Primitive / veterinary. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076871.001).
  • [ISSN] 1463-5216
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Klopfleisch R, Gruber AD: Derlin-1 and stanniocalcin-1 are differentially regulated in metastasizing canine mammary adenocarcinomas. J Comp Pathol; 2009 Aug-Oct;141(2-3):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Derlin-1 and stanniocalcin-1 are differentially regulated in metastasizing canine mammary adenocarcinomas.
  • Laser microdissected tissue samples were prepared from normal canine mammary gland and from simple adenomas, adenocarcinomas and their lymph node metastases.
  • Most adenomas displayed reduced expression of derlin-1 mRNA.
  • Few adenocarcinomas overexpressed derlin-1 mRNA, but all lymph node metastases overexpressed this gene product.
  • Stanniocalcin-1 mRNA was not expressed within adenomas and was reduced in adenocarcinomas and their lymph node metastases.
  • Taken together, these results suggest that malignant behaviour of canine mammary adenocarcinoma is associated with reduced transcription of the stanniocalcin-1 gene and overexpression of the derlin-1 gene.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / genetics. Glycoproteins / genetics. Mammary Neoplasms, Animal / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Adenoma / veterinary. Animals. Biomarkers, Tumor / genetics. Dogs. Female. Gene Expression Regulation, Neoplastic. Microdissection / methods. Microdissection / veterinary. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Reverse Transcriptase Polymerase Chain Reaction / veterinary. Serpins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19515379.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / SERPIN-B5; 0 / Serpins; 76687-96-2 / teleocalcin
  •  go-up   go-down


8. Carneiro FP, Ramalho LN, Britto-Garcia S, Ribeiro-Silva A, Zucoloto S: Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum; 2006 May;49(5):588-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas.
  • PURPOSE: The aim of this study was to investigate the immunohistochemical expression of p16, p53, and p63 proteins according to some pathologic parameters related to colorectal adenomas and adenocarcinomas such as grade of dysplasia and histologic type.
  • METHODS: Immunohistochemistry with the antibodies p16, p53, and p63 was performed in tubular, tubular-villous, and villous adenomas (n = 30) and in well, moderately, and poorly differentiated adenocarcinomas (n = 30).
  • RESULTS: The p16 and p53 labelings were observed in some adenomas and adenocarcinomas but without any association with p63 expression, histologic type, or grade of differentiation of the neoplasm.
  • P63 expression was found mainly in the villous adenomas and in the poorly differentiated adenocarcinomas.
  • The poorly differentiated adenocarcinomas also exhibited coexpression of CK5 and p63.
  • However, p63 expression was closely associated with villous adenomas and poorly differentiated adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma. Adenoma. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575619.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


9. Porta M, Crous-Bou M, Wark PA, Vineis P, Real FX, Malats N, Kampman E: Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res; 2009 Sep-Dec;682(2-3):83-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes.
  • Surprisingly different frequencies and patterns of K-ras mutations are observed in human adenocarcinomas of the pancreas, colorectum and lung.
  • We evaluated all the available types of clinical and epidemiological studies on the relationship between tobacco smoking and the occurrence of K-ras mutations in human adenocarcinomas of the pancreas, colorectum and lung.
  • In pancreatic adenocarcinomas lifetime history of tobacco consumption was not significantly associated with the frequency of K-ras mutations (OR=1.26; 95% CI=0.82-1.94).
  • Similarly, no association was observed between smoking and K-ras mutations in colorectal adenocarcinomas (OR=0.94; CI=0.79-1.12), neither when colorectal adenomas and adenocarcinomas were jointly analyzed (OR=0.96; 95% CI=0.83-1.13).
  • In lung adenocarcinoma, where only 15-25% of cases harbor a K-ras mutation, tumors from smokers were more likely to have K-ras mutations than tumors from non-smokers (OR=3.67; 95% CI=2.47-5.45).
  • Furthermore, in lung adenocarcinomas K-ras mutations have a pattern different from that in pancreatic and colorectal adenocarcinomas.
  • In adenocarcinoma of the lung, smoking may play a role in the occurrence of K-ras mutations.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Pancreatic Neoplasms / genetics. Smoking / adverse effects


10. Fan LF, Dong WG, Jiang CQ, Xia D, Liao F, Yu QF: Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis; 2010 Jan;25(1):17-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas.
  • This study was to detect expressions of the two genes in colorectal adenomas and carcinomas and to analyze the correlation between Musashi-1 and beta1-integrin.
  • METHODS: Musashi-1 and beta1-integrin immunoreactivity was studied immunohistochemically in tissue microarray-based samples containing 69 colorectal adenocarcinomas, eight normal mucosa, and eight adenomas, and their messenger RNA (mRNA) expression level was detected by RT-PCR in resected specimens including the three types of tissue.
  • RESULTS: A percentage of 66.7% (46/69) and 59.2% (41/69) of colorectal adenocarcinomas were immunoreactive with Musashi-1 and beta1-integrin, respectively.
  • beta1-integrin expression was higher in group of adenocarcinomas than that of adenomas (P = 0.0276).
  • Significant differences of Musashi-1 and beta1-integrin mRNA expression levels were found between the normal colorectal mucosa, adenoma, and adenocarcinoma tissues (P = 0.01; P = 0.03, respectively).
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Antigens, CD29 / genetics. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Nerve Tissue Proteins / genetics. RNA-Binding Proteins / genetics. Stem Cells / metabolism


11. Gassler N, Herr I, Schneider A, Penzel R, Langbein L, Schirmacher P, Kopitz J: Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas. J Pathol; 2005 Nov;207(3):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas.
  • In the present study, gene expression, protein synthesis, and enzymatic activity of ACS5 in sporadic colorectal adenocarcinomas, adenomas, and established cell lines were analysed using RT-PCR, western blot analysis, immunofluorescence, and an enzymatic assay.
  • Enhanced expression of ACS5 mRNA and protein as well as enzymatic activity was found in adenomas and in 11 (73%; group 1) of 15 colorectal adenocarcinomas investigated, while a decrease of ACS5 was seen in four tumours (27%; group 2).
  • However, basal ACS5 enzymatic activity was increased as a percentage of the total activity of ACSs in both groups, arguing for an absolute (group 1) or relative (group 2) increase in ACS5 enzymatic activity in all adenocarcinomas investigated.
  • These findings are reflected by in vitro analysis of three established colorectal adenocarcinoma cell lines, in which activity of ACS5 occurred.
  • [MeSH-major] Adenocarcinoma / metabolism. Coenzyme A Ligases / metabolism. Colorectal Neoplasms / metabolism
  • [MeSH-minor] Adenoma / enzymology. Adenoma / genetics. Adenoma / metabolism. Aged. Aged, 80 and over. Cell Line, Tumor. Colon / enzymology. Colon / metabolism. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Neoplasm Proteins / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Rectum / enzymology. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16110457.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.- / acyl CoA synthetase 5
  •  go-up   go-down


12. Klopfleisch R, Gruber AD: Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci; 2009 Aug;87(1):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands.
  • To analyze their role in the malignant progression of canine mammary tumors expression levels of p27 and p21 and its major regulator p53 were compared in simple adenomas, adenocarcinomas of the mammary gland and lymph node metastases with normal mammary gland.
  • Laser microdissection of tissue samples and real-time PCR were used for quantification of mRNA expression levels. p21 was overexpressed in adenocarcinomas, whereas adenomas and metastases expressed p21 more heterogeneously.
  • Comparison of p21 expression in adenocarcinomas and their metastases revealed a significant decrease in expression in metastases.
  • In contrast, p27 expression was reduced in the adenocarcinomas but heterogeneously expressed in adenomas and metastases.
  • [MeSH-major] Adenocarcinoma / veterinary. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Dog Diseases / metabolism. Genes, p53 / physiology. Mammary Neoplasms, Animal / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185891.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Messenger; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


13. Schneider AR, Seifert H, Trojan J, Stein J, Hoepffner NM: Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater--an age-matched, controlled study. Z Gastroenterol; 2005 Oct;43(10):1123-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater--an age-matched, controlled study.
  • METHODS: 26 consecutive patients (16 women, 10 men; median age 59 years) with sporadic adenomas (n = 19) or adenocarcinomas (n = 7) of the ampulla of Vater were retrospectively evaluated.
  • [MeSH-major] Adenocarcinoma / complications. Adenoma / complications. Ampulla of Vater. Common Bile Duct Neoplasms / complications. Intestinal Polyps / epidemiology
  • [MeSH-minor] Adenoma, Villous / complications. Adenoma, Villous / surgery. Adenomatous Polyposis Coli / epidemiology. Adult. Aged. Aged, 80 and over. Colonic Polyps / diagnosis. Colonic Polyps / epidemiology. Colonoscopy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220451.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


1
Advertisement
4. Nowak M, Madej JA, Dziegiel P: Expression of Breast Cancer Resistance Protein (BCRP-1) in canine mammary adenocarcinomas and adenomas. In Vivo; 2009 Sep-Oct;23(5):705-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Breast Cancer Resistance Protein (BCRP-1) in canine mammary adenocarcinomas and adenomas.
  • Localization and intensity of BCRP-1 expression was evaluated in mammary adenocarcinomas and adenomas in dogs.
  • MATERIALS AND METHODS: Materials for the study were sampled in the course of surgery from 54 dogs, of various breeds, aged 6 to 16 years (36 cases of mammary adenocarcinoma and 18 cases of mammary adenoma).
  • RESULTS: Expression of BCRP-1 was detected in over 85% of adenocarcinomas and almost 28% of adenomas.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Adenocarcinoma / veterinary. Adenoma / veterinary. Mammary Neoplasms, Animal / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779104.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Lee SA, Choi SR, Jang JS, Lee JH, Roh MH, Kim SO, Kim MC, Kim SJ, Jeong JS: Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci; 2010 Jul;55(7):1955-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.
  • Despite recent medical advancements, gastric adenoma or adenocarcinoma remains a considerable therapeutic challenge.
  • Endoscopic submucosal dissection (ESD) is a more recent approach that is now commonly used for radical resection of gastric adenoma and adenocarcinoma.
  • AIM AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and interleukin-6 (IL-6) are related to the prognosis of gastric adenocarcinoma.
  • However, the expression of these factors in gastric adenoma/adenocarcinoma following ESD has not been clearly evaluated.
  • Here, we report on our study of the expression of VEGF, EGFR, and IL-6 by immunohistochemical staining in extracted tissue from adenoma or adenocarcinoma of the stomach by ESD and subsequent evaluation of the correlation of VEGF, EGFR, and IL-6 with other clinicopathological parameters.
  • The patient cohort consisted of 102 patients with adenoma or adenocarcinoma of the stomach.
  • RESULTS: Immunohistochemical staining for VEGF and IL-6 was significantly higher in both high grade dysplasia and adenocarcinoma than in low grade dysplasia (P < 0.05).
  • Histological differentiation of adenocarcinoma was related to IL-6 expression (P = 0.028).
  • CONCLUSION: The immunohistochemical expression of IL-6 and VEGF can be considered to be useful for clinical diagnosis and follow-up of adenoma or adenocarcinoma of the stomach.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Interleukin-6 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / pathology. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757047.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


16. Grady WM, Ulrich CM: DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas? Gut; 2007 Mar;56(3):318-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas?

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Gut. 2007 Mar;56(3):380-4 [16891355.001]
  • [Cites] Mutat Res. 2000 May 30;450(1-2):139-53 [10838139.001]
  • [Cites] Histol Histopathol. 2000 Jul;15(3):835-42 [10963127.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27851-7 [10878012.001]
  • [Cites] Mutat Res. 2001 Aug 22;495(1-2):103-15 [11448648.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):168-70 [12107837.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] Oncology. 2002;63(4):393-7 [12417795.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3518S-3521S [12421880.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):625-35 [12727789.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):320-3 [14973087.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):1-8 [15017625.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):281-6 [15140540.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1089-93 [15452166.001]
  • [Cites] Biochemistry. 1996 Jan 30;35(4):1328-34 [8573590.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702 [9671741.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1473-80 [15831531.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):781-9 [16708352.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [CommentOn] Gut. 2007 Mar;56(3):380-4 [16891355.001]
  • (PMID = 17339242.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059045; United States / NCI NIH HHS / CA / R01 CA114467; United States / NCI NIH HHS / CA / R01 CA59045
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 29
  • [Other-IDs] NLM/ PMC1856827
  •  go-up   go-down


17. Fujimoto T, Yoshimatsu K, Watanabe K, Yokomizo H, Otani T, Matsumoto A, Osawa G, Onda M, Ogawa K: Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas. Anticancer Res; 2007 Jan-Feb;27(1A):127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas.
  • MATERIALS AND METHODS: The study population consisted of eleven patients who had undergone resection for colorectal cancer or adenoma from 2000 to 2002.
  • RESULTS: The XBP-1 gene was overexpressed in four cases out of five primary colorectal carcinomas and in four cases out of six colorectal adenomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / biosynthesis. Nuclear Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352224.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / regulatory factor X transcription factors
  •  go-up   go-down


18. Kim JY, Park DY, Kim GH, Choi KU, Lee CH, Huh GY, Sol MY, Song GA, Jeon TY, Kim DH, Sim MS: Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma. Histol Histopathol; 2005 Apr;20(2):543-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma.
  • The purpose of this study was to elucidate Smad4 expression and localization in 65 gastric adenomas, 49 intestinal-type and 39 diffuse type of gastric adenocarcinomas (including 12 cases of fresh frozen tissue) using Real-time RT-PCR and immunohistochemistry.
  • Real-time RT-PCR showed that intestinal type gastric adenocarcinomas have higher Smad4 mRNA expression than diffuse type gastric adenocarcinomas.
  • Immunohistochemical stain for Smad4 revealed that expression of Smad4 was significantly lower in diffuse-type gastric adenocarcinoma than intestinal-type gastric adenocarcinomas.
  • Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted.
  • These results suggest that Smad4 might play different roles in human gastric carcinogenesis, especially between intestinal type and diffuse type of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Trans-Activators / genetics. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736060.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta
  •  go-up   go-down


19. Iurin AG, Koval'skiĭ GB: [Proliferative activity by expression of antigen Ki-67 in solitary and multiple synchronous epithelial tumors of the colon]. Arkh Patol; 2005 Sep-Oct;67(5):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proliferative activity of sigmoid and rectal mucosa, and that of single and multiple (synchronous) adenomas and adenocarcinomas of the colon has been studied.
  • A significant difference between antigen Ki-67 expression index in normal mucosa, adenomas and adenocarcinomas, and also in single and multiple colorectal cancers has been revealed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Ki-67 Antigen / analysis. Neoplasms, Multiple Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323481.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


20. Simeonov R, Simeonova G: Quantitative analysis in spontaneous canine anal sac gland adenomas and carcinomas. Res Vet Sci; 2008 Dec;85(3):559-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis in spontaneous canine anal sac gland adenomas and carcinomas.
  • Stained cytological specimens from 7 canine anal sac gland adenomas and 11 canine anal sac gland carcinomas were analyzed by computer-assisted nuclear morphometry.
  • The study aimed to evaluate (1) the possibility of using nuclear cytomorphometry as an auxiliary diagnostic method to differentiate between canine anal sac gland adenomas and adenocarcinomas, and (2) the prognostic value of nuclear morphometry in canine anal sac gland adenocarcinomas.
  • The results indicated that (1) MNA, MNP, MND and NR could be used as effective auxiliary tools for differential diagnosis between canine anal sac gland adenomas and adenocarcinomas, and (2) MNA, MNP and MND are reliable prognostic indicators for canine anal sac gland adenocarcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457852.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Wang Y, Zhou ZG, Xia QJ, Zhang WY, Li HG, Wang R: [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):465-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance].
  • OBJECTIVE: To investigate the expression differences of minichromosome maintenance 2 (MCM2) mRNA and protein among colon adenocarcinoma, colon adenoma and normal mucosa, and among different clinicopathological types of adenomas.
  • METHODS: Fifty specimens, including 33 colonic adenomas, 12 colonic adenocarcinomas and 5 normal colonic mucosa were selected.
  • Expression differences of MCM2 mRNA among the colonic adenocarcinoma, adenoma and normal colonic mucosa were evaluated by REST-XL software.
  • RESULTS: The expression of MCM2 was observed in the basal third to half of the colonic crypts in normal mucosa, while throughout the epithelium in the colonic adenocarcinomas and adenomas.
  • However, the expression of MCM2 mRNA in the adenocarcinomas was significantly higher than that in the adenomas(P=0.001).
  • The MCM2 mRNA expression was elevated in the adenoma with villous type, in the conditions of high-grade dysplasia, larger size, sessile morphology and in patients of older ages, but the difference was not significant by REST-XL (P>0.05).
  • CONCLUSION: The difference of MCM2 expression between the adenoma and the adenocarcinoma indicates its potential value in the early diagnosis of colonic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Cycle Proteins / metabolism. Colonic Neoplasms / metabolism. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803052.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


22. Arévalo F, Arias Stella C, Monge E: [Immunoexpression of p53 and cyclin D1 in adenomas of the gallbladder]. Rev Esp Enferm Dig; 2007 Dec;99(12):694-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoexpression of p53 and cyclin D1 in adenomas of the gallbladder].
  • [Transliterated title] Inmunoexpresión de p53 y ciclina D1 en adenomas de vesícula biliar.
  • INTRODUCTION: Gallbladder adenomas are infrequent neoplasms whose relation to adenocarcinoma is not well understood.
  • It has been suggested that adenomas and adenocarcinomas follow different molecular pathways.
  • MATERIAL AND METHODS: This is a comparative, cross-sectional study in which we compared p53 and D1 cyclin expression in adenomas and adenocarcinomas of the gallbladder.
  • Expression of p53 occurred in 83.3% of adenocarcinomas and in 16.6% of adenomas (p = 0.003).
  • D1 cyclin was expressed in a similar number of adenomas and adenocarcinomas.
  • CONCLUSION: Our results support the hypothesis that p53 is an important step in the pathogenesis of adenocarcinomas but not of adenomas of the gallbladder.
  • [MeSH-major] Adenoma / metabolism. Cyclin D1 / biosynthesis. Gallbladder Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290692.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


23. Gopalan V, Smith RA, Nassiri MR, Yasuda K, Salajegheh A, Kim SY, Ho YH, Weinstein S, Tang JC, Lam AK: GAEC1 and colorectal cancer: a study of the relationships between a novel oncogene and clinicopathologic features. Hum Pathol; 2010 Jul;41(7):1009-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of the present study are to identify the copy number of GAEC1 in different colorectal tissues including carcinomas, adenomas, and nonneoplastic tissues and characterize any links to pathologic factors.
  • The copy number of GAEC1 was studied by evaluating the quantitative amplification of GAEC1 DNA in 259 colorectal tissues (144 adenocarcinomas, 31 adenomas, and 84 nonneoplastic tissues) using real-time polymerase chain reaction.
  • Copy number of GAEC1 DNA in colorectal adenocarcinomas was higher in comparison with nonneoplastic colorectum.
  • Seventy-nine percent of the colorectal adenocarcinomas showed amplification and 15% showed deletion of GAEC1 (P < .0001).
  • Of the adenomas, 90% showed deletion of GAEC1, with the remaining 10% showing normal copy number.
  • The differences in GAEC1 copy number between colorectal adenocarcinoma, colorectal adenoma, and nonneoplastic colorectal tissue are significant (P < .0001).
  • GAEC1 copy number was significantly higher in adenocarcinomas located in distal colorectum compared with proximal colon (P = .03).
  • In conclusion, GAEC1 copy number was significantly different between colorectal adenocarcinomas, adenomas, and nonneoplastic colorectal tissues.
  • These findings along with previous work in esophageal cancer imply that GAEC1 is commonly involved in the pathogenesis of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Nuclear Proteins / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20236690.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GAEC1 protein, human; 0 / Mucins; 0 / Nuclear Proteins
  •  go-up   go-down


24. Cho EY, Kim KM, Park CK, Kim JJ, Sohn TS, Kim DW: AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas. APMIS; 2007 Jun;115(6):713-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
  • Alpha-methylacyl-CoA racemase (AMACR) is a novel tumor biomarker expressed in a number of neoplasms, including colorectal and prostatic adenocarcinomas.
  • Using immunohistochemistry we studied the expression of AMACR in normal gastric mucosa (n=32), intestinal metaplasia (n=26), adenomas (n=29) and adenocarcinomas (n=132) of the stomach from 135 patients.
  • Synchronous adenocarcinomas arising in the background of adenomas were observed in 26 cases.
  • Tissue from intestinal metaplasia, adenomas, and adenocarcinomas was positive in 7.7% (2/26), 79.3% (23/29), and 62.9% (83/132) of cases, respectively.
  • The difference in AMACR expression between adenomas or adenocarcinomas and non-neoplastic mucosa was statistically significant (p=0.0001).
  • Our results indicate that as well as being an additional diagnostic tool, altered AMACR expression in gastric adenomas and intestinal-type carcinomas suggests that AMACR may be involved early in the development of intestinal-type gastric carcinomas.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / analysis. Intestinal Neoplasms / metabolism. Intestines / pathology. Racemases and Epimerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550379.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


25. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • Adenocarcinomas of the bladder are rare, with the diagnosis dependent on exclusion of secondary involvement by direct extension or metastatic spread from other sites.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • We identified 37 primary infiltrating adenocarcinomas of the bladder, which included signet ring cell carcinomas (n=11), urachal adenocarcinomas (n=5), and enteric adenocarcinoma (n=21).
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • Of the 37 adenocarcinomas, all were negative for PSA and PSAP (0/37; 0%).
  • In contrast, a minority of bladder adenocarcinomas was labeled with the prostate antigens P501S and PSMA.
  • P501S showed moderate diffuse cytoplasmic staining in 4/37 cases (11%), including 3 enteric-type adenocarcinomas and 1 mucinous adenocarcinoma.
  • Additionally, 1 case of adenocarcinoma in situ demonstrated diffuse cytoplasmic staining for P501S.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • PSMA showed diffuse cytoplasmic staining in 4/37 (11%) infiltrating adenocarcinomas (including 1 signet ring carcinoma and 3 enteric-type adenocarcinomas), and in 1 case of adenocarcinoma in situ.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


26. Ayhan S, Isisag A, Saruc M, Nese N, Demir MA, Kucukmetin NT: The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology; 2010 Mar-Apr;57(98):251-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This study is aimed to investigate abnormal expression of the Rb protein (pRb), p16(INK4a) (p16) and cyclin D1 in colorectal adenomas and adenocarcinomas and to assess the possible alterations in Rb pathway in colorectal carcinogenesis.
  • METHODOLOGY: 44 cases of colorectal adenoma and 44 cases of colorectal adenocarcinoma were examined histopathologically and immunohistochemically using monoclonal antibodies to identify abnormalities of pRb, p16, and cyclin D1 expression.
  • RESULTS: In 70.5% of the adenomas and 97.7% of the adenocarcinomas, an overexpression of pRb was found.
  • There was a statistically significant relationship between the immunoreactivity of pRb and villous/tubulovillous types of adenomas (p < 0.05).
  • There was a loss of p16 expression in 84.1% of adenomas and 61.4% of adenocarcinomas.
  • Statistically significantly, the p16 overexpression was not seen in any of tubular adenomas (p < 0.001).
  • Overexpression of cyclin D1 was found in only 9.1% of adenomas, while 31.8% of adenocarcinomas overexpressed this protein.
  • Loss of expression of cyclin D1 was similar in adenomas and adenocarcinomas (27.3% and 25%, respectively).
  • Staining degrees of all three cell cycle proteins were shown to be statistically different in adenomas and adenocarcinomas, for pRb (p = 0.001), for p16 ( p = 0.045), and cyclin D1 ( p = 0.05).
  • Also, there was only a mild agreement with respect to p16 and cyclin D1 relationship between for adenomas ( K = +0.28 p = 0.051) and for adenocarcinomas ( K = +0.35 p = 0.017).
  • CONCLUSIONS: pRb, p16 and cyclin D1 are shown to be aberrantly expressed in both colorectal adenomas and adenocarcinomas.
  • It can be claimed that disturbances in Rb pathway take part in colonic carcinogenesis and pRb, p16 and cyclin D1 play an ever increasing role in the further stages of adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Retinoblastoma Protein / metabolism


27. Takeuchi H, Saoo K, Matsuda Y, Yokohira M, Yamakawa K, Zeng Y, Kuno T, Kamataki T, Imaida K: 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Mol Med Rep; 2009 Jul-Aug;2(4):585-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.
  • Previously, we demonstrated that 8-methoxypsoralen (methoxsalen), a potent human cytochrome P450 2A6 (CYP2A6) inhibitor, strongly suppresses lung adenoma induction by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice.
  • In the present study, we examined the inhibitory effects of methoxsalen on the development of lung adenocarcinomas, as well as on adenomas and alveolar hyperplasia.
  • The experiments were terminated 52 weeks after the first methoxsalen treatment, and lung adenomas and adenocarcinomas were analyzed histopathologically.
  • Pretreatment with methoxsalen significantly reduced the incidence of adenocarcinomas from 94.7 to 46.7% (12.5 mg/kg) and 44.4% (1.25 mg/kg), and their tumor multiplicity from 4.68 to 0.87 (12.5 mg/kg) and 0.61 (1.25 mg/kg) tumors/mouse.
  • The tumor multiplicity of adenomas and adenocarcinomas in the methoxsalen-treated groups was significantly reduced from 12.47 to 5.67 (12.5 mg/kg) and 4.28 (1.25 mg/kg) tumors/mouse.
  • Approximately 60% of the adenocarcinomas arose within adenomas.
  • In comparing the methoxsalen + NNK and NNK alone groups, there was no significant difference in the frequency of such compound lesions, indicating that pretreatment with methoxsalen did not suppress the eventual progression of adenomas to adenocarcinomas.
  • These results clearly demonstrate that methoxsalen, a potent human CYP2A6 inhibitor, inhibits not only lung adenoma but also adenocarcinoma development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21475870.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


28. Shi C, Scudiere JR, Cornish TC, Lam-Himlin D, Park JY, Fox MR, Montgomery EA: Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. Am J Surg Pathol; 2010 Sep;34(9):1344-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile.
  • Clear cell change is seen in <1% of colonic tubular adenomas (TAs) and remains incompletely characterized.
  • Associated adenocarcinomas can also demonstrate a clear cell phenotype.
  • Eleven TAs with at least focal clear cell change with or without associated invasive adenocarcinoma, from 10 patients were studied.
  • Two were associated with invasive clear cell adenocarcinoma.
  • The adenomas and adenocarcinomas ranged from 0.5 to 3.5 cm.
  • On immunohistochemical studies, the clear cells had decreased MUC2 labeling compared with the surrounding conventional adenoma in 9 of 11 (88%) cases, including the 2 clear cell adenocarcinomas.
  • Compared with background TA, both increased and decreased expression of CK7, CK20 (in quantity), and CDX2 (in intensity) were observed in the clear cells of TAs and adenocarcinomas.
  • One of the clear cell adenocarcinomas was CK20, CK7, CDX2 and the other was CK20, CK7, CDX2-focal positive.
  • Thus, although the clear cells have different MUC protein profiles than the background adenomatous epithelium, invasive clear cell adenocarcinomas retained the typical CK20(+)/CK7(-) profile of conventional adenocarcinomas.
  • Our results indicate that clear cell adenocarcinomas can be primary to the colorectum with identifiable precursors.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Colonic Neoplasms / pathology. Mucins / metabolism. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697252.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


29. Hong R, Lim SC: Pathological significance of connexin 26 expression in colorectal adenocarcinoma. Oncol Rep; 2008 Apr;19(4):913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological significance of connexin 26 expression in colorectal adenocarcinoma.
  • This study was conducted to determine the level of expression and cellular localization of connexin 26 (Cx26) and the expression of p53 in colorectal adenocarcinoma as well as their relationship to clinicopathological features.
  • Immunohistochemical staining was performed in 130 colorectal adenocarcinoma cases.
  • There was a statistical significant difference in the Cx26 expression level among normal epithelium (NE), adenomas and adenocarcinomas (p<0.001).
  • Of the 130 adenocarcinomas, 48.5% were positive for Cx26.
  • All of the adenoma and NE samples were positive for Cx26 expression; however, the level of expression of Cx26 in adenomas was smaller than the level of expression for NE.
  • Cytoplasmic staining for Cx26 was observed in the adenocarcinomas (23.8%), but was not observed in the adenoma and NE samples.
  • Expression of p53 was positive for 50% of the adenocarcinomas, and the level of p53 was increased in a reverse proportion to the level of Cx26 intercellular staining.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Connexins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


30. Lozynska M: The prognostic value of cytogenetic markers for early diagnosis of colorectal cancer. Exp Oncol; 2009 Dec;31(4):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of cytogenetic markers for early diagnosis of colorectal cancer.
  • AIM: To investigate the spectrum of chromosome changes in colorectal adenomas and adenocarcinomas and to evaluate the prognostic significance of the chromosome rearrangements.
  • METHODS: The study was carried out using the cytogenetic analysis of biopsy specimens (n = 56) of single and multiply adenomas (familial adenomatous syndromes; n = 38) and adenocarcinomas (n = 18).
  • RESULTS: The karyotype of adenomas was normal in the majority of cases, but some adenomas with severe dysplasia of epithelium carry the quantitative chromosome abnormalities and structural rearrangements.
  • The combination of additional copies of chromosomes 13, 18, 20 in adenomas points on an unfavorable prognosis.
  • The chromosome abnormalities were found in 100% of adenocarcinomas biopsy specimens.
  • CONCLUSIONS: The transition from colorectal adenomas to adenocarcinomas is accompanied by elevation of chromosome abnormalities level, in particular, by increased clonal variety, selective accumulation of the copies of chromosomes 2, 3, 20, 16, with simultaneous monosomy of chromosomes 17, 18, 8, 6, 14, and del 1p.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Biomarkers, Tumor / genetics. Chromosome Aberrations. Colorectal Neoplasms / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010528.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


31. Park SH, Kim SY, Lee SS, Bogoni L, Kim AY, Yang SK, Myung SJ, Byeon JS, Ye BD, Ha HK: Sensitivity of CT colonography for nonpolypoid colorectal lesions interpreted by human readers and with computer-aided detection. AJR Am J Roentgenol; 2009 Jul;193(1):70-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A computerized database search for a 33-month period found 21 patients who had undergone both colonoscopy and CTC and who had a total of 23 genuinely nonpolypoid colorectal lesions: eight adenomas (9-30 mm in width), 10 stage Tis or T1 adenocarcinomas (10-25 mm), and five nonadenomatous lesions (8-20 mm).
  • RESULTS: The sensitivities of human readers for nonpolypoid adenomatous lesions (i.e., both adenomas and adenocarcinomas), adenocarcinomas, and nonadenomatous lesions were 66.7% (12/18), 90% (9/10), and 0% (0/5), respectively.
  • A 10-mm stage T1 adenocarcinoma was missed by a human reader on blinded review but was detected with CAD.
  • Both human readers and CAD yielded significantly higher sensitivity for adenomatous lesions than for nonadenomatous lesions (p = 0.014 and 0.046, respectively) and for adenocarcinomas than for noncancerous lesions (p = 0.003 and 0.0001, respectively).
  • CONCLUSION: CTC showed a high sensitivity for nonpolypoid stage Tis and T1 adenocarcinomas 10 mm or greater in width despite the limited overall sensitivity for nonpolypoid adenomatous lesions, when performed using cathartic preparation and fecal tagging.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542397.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Lee DS, Kang SB, Baek JT, Nam SW, Lee KM, Ahn BM, Lee EH, Han SW, Chung IS: [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2005 Jun;45(6):394-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical expression of bcl-2, bcl-xL, bax, and p53 proteins according to the pathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in the gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal bcl-2, bcl-xL, bax, p53 antibodies were performed on paraffin embedded specimens from forty-one gastric adenomas and 100 gastric adenocarcinomas.
  • RESULTS: The expression rate of bcl-2 was higher in adenomas (34.2%), especially in high grade dysplasia (52.4%), than adenocarcinomas (2.0%).
  • The expression rate of bcl-xL was higher in adenocarcinomas (55.0%) than adenomas (22%).
  • The expression rate of the bax was higher in adenocarcinomas (58.0%) than adenomas (14.6%).
  • In the adenocarcinoma, the bax expression was significantly related with the depth of invasion, lymph node metastasis, and TNM stage.
  • The expression rate of p53 was higher in adenocarcinomas (64.0%) than adenomas (14.6%).
  • CONCLUSIONS: Bcl-2 protein would be related with the development of gastric adenoma, especially with high grade dysplasia.
  • Bcl-xL and p53 proteins would be involved in the development of relatively early stage of gastric adenocarcinoma but not in tumor progression.
  • Bax protein would be involved in the development of gastric adenocarcinoma and related with depth of invasion, lymph node metastasis, and TNM stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973073.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


33. Scheiden R, Pescatore P, Wagener Y, Kieffer N, Capesius C: Colon cancer in Luxembourg: a national population-based data report, 1988-1998. BMC Cancer; 2005;5:52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to determine a strategy for early detection of colon cancer in the Grand-Duchy of Luxembourg, all consecutive colon adenocarcinomas diagnosed during the period 1988-1998 at a nation-wide level were reviewed.
  • METHODS: The population-based data of the national Morphologic Tumour Registry report all new high-grade adenomas (i.e. high-grade intraepithelial adenomatous neoplasias) and all consecutive new invasive adenocarcinomas of the colon diagnosed in the central department of pathology.
  • RESULTS: Over the study period, 254 new colonic high-grade adenomas and 1379 new invasive adenocarcinomas were found; the crude incidence rates of colon adenocarcinomas grew steadily by 30%.
  • Comparing the two 5-year periods 1988-1992 and 1994-1998, the crude incidence rates of high-grade adenomas (stage 0) rose by 190%, that of stage I cases by 14.3%, stage II cases 12.9% and stage III cases 38.5%, whereas the crude incidence rates of stage IV cases decreased by 11.8%.
  • The high-grade adenoma/adenocarcinoma ratio increased.
  • The right-sided colonic adenocarcinomas in elderly patients (>69 years) increased by 76%.
  • CONCLUSION: The increasing incidence rates of colon adenocarcinomas, the persistence of advanced tumour stages (stage III), the mortality rates which remain stable, and the changing trends in the age- and sub-site distribution underline the need for preventive measures at the age of 50 in asymptomatic patients to reduce mortality from colo(rectal) cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2001 Dec 1;111(8):593-601 [11755501.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2547-54 [11745188.001]
  • [Cites] Oncologist. 2002;7(3):200-4 [12065791.001]
  • [Cites] Gut. 2002 Jul;51(1):60-4 [12077093.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Am Surg. 2002 Oct;68(10):871-6 [12412713.001]
  • [Cites] Eur J Cancer Prev. 2002 Dec;11(6):529-34 [12457104.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):38-43 [12604723.001]
  • [Cites] Scand J Surg. 2003;92(1):5-9 [12705545.001]
  • [Cites] An Sist Sanit Navar. 2003 Jan-Apr;26(1):79-97 [12759713.001]
  • [Cites] N Z Med J. 2003 May 16;116(1174):U437 [12766783.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):886-90 [12658426.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S32-43 [14530656.001]
  • [Cites] Am Surg. 2003 Oct;69(10):866-72 [14570365.001]
  • [Cites] Dig Dis. 2003;21(4):315-9 [14752221.001]
  • [Cites] W V Med J. 2003 Sep-Oct;99(5):182-6 [14959509.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] BMC Cancer. 2003 Oct 21;3:27 [14567762.001]
  • [Cites] IARC Sci Publ. 1992;(120):178-861 [1284601.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):12-20 [8115781.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1781-5 [12050337.001]
  • (PMID = 15913456.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1173094
  •  go-up   go-down


34. Kang WY, Chen WT, Wu MT, Chai CY: The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int J Colorectal Dis; 2007 Aug;22(8):869-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma.
  • BACKGROUND: The aim of our study was to analyze the expression and possible role of CD66a in colorectal adenoma and adenocarcinoma and the relationship between its expression and pre-operation serum carcinoembryonic antigen (CEA) level and tumor stage in patients with colorectal adenocarcinomas.
  • METHODS: Paraffin-embedded sections from 184 patients including 42 colorectal adenomas with low-grade dysplasia, 43 adenomas with high-grade dysplasia, and 99 adenocarcinomas were collected for this study.
  • RESULTS: The expression of CD66a was found not only in the apical membrane of neoplastic glands but also in secretion within the lumen of the neoplastic glands including adenomas and adenocarcinomas.
  • Expressions of secreted CD66a were of higher level in adenocarcinoma than in adenoma with high-grade dysplasia and adenoma with low-grade dysplasia (p < 0.0001).
  • High expression of secreted CD66a was also associated with tumor stage, invasion, and pre-operation serum CEA level of patients with colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Adenoma / immunology. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Colorectal Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143599.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CTNNB1 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / beta Catenin
  •  go-up   go-down


35. Vainer B, Horn T, Nielsen OH: Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: a comparative study of inflammatory bowel disease and colonic neoplasms. Scand J Gastroenterol; 2006 Mar;41(3):318-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to assess the ICAM-1 expression in human colonic tissue representing UC, Crohn's disease (CD), adenomas, and adenocarcinomas, with special attention to the epithelium.
  • Colonic tissue from 10 patients with UC, 10 with CD, 32 adenomas, 27 adenocarcinomas, and 10 lymph node metastases were included.
  • Similar observations were made in the case of adenomas and adenocarcinomas, but in adenocarcinomas the epithelial ICAM-1 was more diffuse and not related solely to sites of surface destruction.

  • Genetic Alliance. consumer health - Inflammatory bowel disease 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497620.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


36. Tanaka A, Takemura-Tsukashita S, Kushima R, Sugihara H, Fujiyama Y, Hattori T: Low-grade gastric adenomas/dysplasias: phenotypic expression, DNA ploidy pattern, and LOH at microsatellites linked to the APC gene. Pathol Res Pract; 2008;204(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade gastric adenomas/dysplasias: phenotypic expression, DNA ploidy pattern, and LOH at microsatellites linked to the APC gene.
  • The adenoma-adenocarcinoma sequence in the colon is generally accepted.
  • We analyzed the phenotypes, DNA ploidy patterns, and microsatellite regions linked to adenomatous polyposis coli (APC) gene on chromosome 5q of low-grade gastric adenomas/dysplasias, Vienna Category 3, to investigate whether these lesions have the potential to become adenocarcinomas.
  • None of the 15 cases showed coexisting high-grade adenomas/dysplasias or adenocarcinoma.
  • According to previous studies, most gastric adenocarcinomas have the gastric phenotype and no 5q-LOH.
  • These results suggest that low-grade gastric adenomas/dysplasias, Vienna category 3, seldom progress to gastric adenocarcinomas of the differentiated type.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Chromosomes, Human, Pair 5. Gene Expression Regulation, Neoplastic. Genes, APC. Loss of Heterozygosity. Microsatellite Repeats. Ploidies. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964080.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


37. Vinci A, Bacci B, Benazzi C, Caldin M, Sarli G: Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits. J Comp Pathol; 2010 May;142(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial adenocarcinoma is the most common uterine tumour of domestic rabbits.
  • The present immunohistochemical study examined the expression of cytokeratin 19 (CK19), the progesterone receptor (PR), the proliferation-associated antigen Ki-67 and telomerase in normal rabbit uterine tissue and examples of endometrial hyperplasia, adenoma and adenocarcinoma.
  • Tubulopapillary adenomas and adenocarcinomas were the most common histological subtypes in this series.
  • Cytoplasmic expression of CK19 was recorded in two of three samples of normal endometrium and in one of three samples of endometrial hyperplasia, in all adenomas and five of six adenocarcinomas.
  • PR was expressed within the nucleus of normal endometrial cells and in one of three samples of endometrial hyperplasia, each of four adenomas and in four of six adenocarcinomas.
  • Nuclear labelling of telomerase activity was found in one of three normal uteri, all samples of endometrial hyperplasia, two of four adenomas, but none of the adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Animals. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Ki-67 Antigen / metabolism. Mitotic Index. Progesterone / metabolism. Prognosis. Rabbits. Telomerase / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20096851.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


38. Nowicki MJ, Bishop PR, Subramony C, Wyatt-Ashmead J, May W, Crawford M: Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion. J Pediatr Gastroenterol Nutr; 2005 Nov;41(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chicken-skin mucosa (CSM) is an endoscopic finding initially described associated with adenomatous polyps and adenocarcinoma, suggesting a preneoplastic lesion.
  • To determine whether CSM represents a preneoplastic lesion, we studied endoscopic colonic mucosal biopsies for markers of cell replication (Ki-67) and malignant transformation (p53) in mucosal biopsies of CSM, normal colonic tissue, tubular adenomas, and adenocarcinomas.
  • The degree of Ki-67-positive staining cells was similar for CSM and normal colonic tissue, whereas there was significantly increased staining for both tubular adenomas and adenocarcinomas.
  • There was no evidence of p53 staining in CSM and normal colonic mucosa, whereas there was varying degrees of staining in tubular adenomas and adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Child. Child, Preschool. Colon / pathology. Colonoscopy. Female. Humans. Immunohistochemistry. Male. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254516.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


39. Lee SW, Kang SB, Kim YS, Nam SW, Lee DS, Lee HK, Han SW: [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2007 Mar;49(3):152-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical overexpression of c-erbB-2 and c-met proteins according to the histopathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal c-erbB-2 and c-met antibodies was performed on paraffin embedded specimens in 43 adenomas and 44 adenocarcinomas.
  • RESULTS: The expression rate of c-erbB-2 was higher in adenomas (91%) than adenocarcinomas (30%).
  • The expression rate of c-met was higher in adenocarcinomas (77%) than adenomas (49%).
  • In adenoma, the expression rate of c-met was higher in high grade dysplasia (94%) than in low grade dysplasia (22%).
  • In adenocarcinoma, c-met expression was significantly related with lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-met / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism


40. Ilha MR, Newman SJ, van Amstel S, Fecteau KA, Rohrbach BW: Uterine lesions in 32 female miniature pet pigs. Vet Pathol; 2010 Nov;47(6):1071-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nodular endometrial lesions-including adenocarcinomas, adenomas, and/or adenomyosis-were present in 10 pigs, 3 of which had concurrent smooth muscle tumors.
  • In uterine sections with cystic endometrial hyperplasia, adenomyosis, or adenomas, approximately 70% of epithelial nuclei expressed estrogen receptor and progesterone receptor immunohistochemically; in adenocarcinomas, expression was 20%.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / veterinary. Adenoma / pathology. Adenoma / veterinary. Animals. Broad Ligament / pathology. Endometrial Hyperplasia / pathology. Endometrial Hyperplasia / veterinary. Endometrium / pathology. Estrogens / blood. Female. Leiomyoma / pathology. Leiomyoma / veterinary. Leiomyosarcoma / pathology. Leiomyosarcoma / veterinary. Progesterone / blood. Pyometra / pathology. Pyometra / veterinary. Swine. Uterine Neoplasms / pathology. Uterine Neoplasms / veterinary. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20817893.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


41. Gostjeva EV, Zukerberg L, Chung D, Thilly WG: Bell-shaped nuclei dividing by symmetrical and asymmetrical nuclear fission have qualities of stem cells in human colonic embryogenesis and carcinogenesis. Cancer Genet Cytogenet; 2006 Jan 1;164(1):16-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large cell nuclei with at least eight distinct morphologies have been discovered throughout the fetal gut (5-7 weeks), colonic adenomas, and adenocarcinomas, five of which are not present in the normal adult colon.
  • Cells containing these differentiated nuclear forms subsequently divide extra-syncytially by mitoses that form clonal populations of cells with identical nuclear morphotypes in embryos, adenomas, adenocarcinomas, and metastases.
  • Cells with bell-shaped nuclei thus appear to be responsible for both net growth and differentiation in the embryonic gut, adenomas, and adenocarcinomas, and fulfill the requirements for post-embryonic stem cells in colon organogenesis and carcinogenesis.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364758.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Gui X, Guzman G, Dobner PR, Kadkol SS: Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides; 2008 Sep;29(9):1609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma.
  • NT is expressed in fetal but not differentiated colonic epithelium and is re-expressed in colonic adenocarcinoma.
  • To further understand the possible role of NTSR1 expression in colonic tumorigenesis and progression, we examined NTSR1 mRNA by in situ hybridization in normal colonic mucosa, adenomas, and colonic adenocarcinomas.
  • NTSR1 mRNA expression was undetectable or weak in superficial differentiated epithelial cells of normal colonic epithelium, but adenomas and adenocarcinomas showed moderate to strong expression (p<0.05).
  • Adenocarcinomas showed a higher level of expression compared to adenomas (p<0.05).
  • Furthermore, adenocarcinomas that infiltrated into and beyond the muscularis propria showed a higher intensity of NTSR1 expression compared with tumors that were localized to the mucosa or submucosa.
  • These results suggest that increased NTSR1 expression may be an early event during colonic tumorigenesis and also contribute to tumor progression and aggressive behavior in colonic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Receptors, Neurotensin / biosynthesis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541341.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Neurotensin; 0 / neurotensin type 1 receptor
  •  go-up   go-down


43. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA: The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology; 2009 May;136(5):1669-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By contrast, increased HuR expression and cytoplasmic localization were observed in 76% of adenomas and 94% of adenocarcinomas, and TTP expression was lost in >75% of adenomas and adenocarcinomas.
  • In both adenomas and adenocarcinomas, COX-2 overexpression was associated with increased HuR and decreased TTP (P < .0001); similar associations were observed in colon cancer cells.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Cell Line, Tumor. Cytoplasm / metabolism. ELAV Proteins. ELAV-Like Protein 1. HeLa Cells. Humans. Immunohistochemistry. RNA, Messenger / analysis. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 May;128(5):1445-61 [15887126.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2157-61 [15781626.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D111-4 [16381826.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Cancer. 2006;5:37 [16982006.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Feb;8(2):113-26 [17245413.001]
  • [Cites] J Cell Biochem. 2007 Apr 15;100(6):1477-92 [17133347.001]
  • [Cites] Arch Biochem Biophys. 2007 Jun 15;462(2):278-85 [17517366.001]
  • [Cites] Expert Opin Biol Ther. 2007 Oct;7(10):1515-29 [17916044.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1124-36 [18644977.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2030-42, 2042.e1-3 [18824170.001]
  • [Cites] Mol Cell. 2005 Sep 16;19(6):777-89 [16168373.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):125-31 [10721704.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11750-7 [10766797.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17827-37 [10751406.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33951-6 [10930401.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1469-74 [11506952.001]
  • [Cites] J Clin Invest. 2001 Dec;108(11):1657-65 [11733561.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):1037-41 [12003384.001]
  • [Cites] EMBO Rep. 2003 Apr;4(4):394-9 [12671683.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13928-35 [12578839.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3554-61 [12789264.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:52-71 [12795048.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7146-54 [14562043.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7591-4 [14633672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2011-6 [14769925.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32393-400 [15187092.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2556-9 [7780968.001]
  • [Cites] EMBO J. 1998 Jun 15;17(12):3448-60 [9628880.001]
  • [CommentIn] Gastroenterology. 2009 May;136(5):1495-8 [19327732.001]
  • (PMID = 19208339.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017698; United States / NCRR NIH HHS / RR / P20 RR017698; United States / NCI NIH HHS / CA / R01 CA134609
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Tristetraprolin; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ NIHMS488861; NLM/ PMC3742387
  •  go-up   go-down


44. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


45. Hughes GK, Miszkiel KA: Imaging of the lacrimal gland. Semin Ultrasound CT MR; 2006 Dec;27(6):476-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article details traditional and new imaging techniques used in investigating such pathology and discusses the imaging findings and patterns of spread characteristic of various neoplastic, inflammatory, and structural processes ranging from benign adenomas, adenocarcinomas, and lymphomas to sarcoidosis, Mickulicz's syndrome, histiocytosis, and benign dacrocysts.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233230.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


46. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S: Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer; 2008 Jan 29;8:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
  • METHODS: By immunohistochemistry, we assessed COX-2 expression in 24 hyperplastic polyps, 7 sessile serrated polyp/adenomas (SSA), 5 mixed polyps with SSA and adenoma, 27 traditional serrated adenomas, 515 non-serrated adenomas (tubular adenoma, tubulovillous adenoma and villous adenoma), 33 adenomas with intramucosal carcinomas, 96 adenocarcinomas with serration (corkscrew gland) and 111 adenocarcinomas without serration.
  • RESULTS: Strong (2+) COX-2 overexpression was more common in non-serrated adenomas (28% = 143/515) than in hyperplastic polyps (4.2% = 1/24, p = 0.008) and serrated polyps (7 SSAs and 5 mixed polyps) (0% = 0/12, p = 0.04).
  • Furthermore, any (1+/2+) COX-2 overexpression was more frequent in non-serrated adenomas (60% = 307/515) than in hyperplastic polyps (13% = 3/24, p < 0.0001) and serrated polyps (SSAs and mixed polyps) (25% = 3/12, p = 0.03).
  • Traditional serrated adenomas and non-serrated adenomas showed similar frequencies of COX-2 overexpression.
  • Regardless of serration, COX-2 overexpression was frequent (approximately 85%) in colorectal adenocarcinomas.
  • Tumor location was not significantly correlated with COX-2 overexpression, although there was a trend towards higher frequencies of COX-2 overexpression in distal tumors (than proximal tumors) among hyperplastic polyps, SSAs, mixed polyps, traditional serrated adenomas and adenocarcinomas.
  • CONCLUSION: COX-2 overexpression is infrequent in hyperplastic polyp, SSA and mixed polyp with SSA and adenoma, compared to non-serrated and serrated adenoma.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1998 Jul;28(7):421-6 [9739782.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4044-8 [10945606.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):350-8 [10419916.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8465-71 [15623626.001]
  • [Cites] Dig Dis Sci. 2004 Nov-Dec;49(11-12):1906-11 [15628724.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):130-8 [15654792.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):429-36 [15767794.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4754-60 [16000571.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6738-44 [16166455.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Oncology. 2005;69 Suppl 1:33-7 [16210875.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]
  • [Cites] BMC Cancer. 2006;6:9 [16409625.001]
  • [Cites] Histopathology. 2006 Mar;48(4):431-7 [16487365.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):458-64 [16820091.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] BMC Cancer. 2006;6:181 [16831226.001]
  • [Cites] J Pathol. 2006 Oct;210(2):137-40 [16917802.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1319-23 [11584208.001]
  • [Cites] Int J Colorectal Dis. 2002 May;17(3):144-9 [12049307.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):705-8 [12598303.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):786-92 [12794581.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Aug;129(8):449-55 [12884030.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):267-71 [14734479.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):213-9 [14745394.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Jun;16(6):619-25 [15167166.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Ann Intern Med. 1994 Aug 15;121(4):241-6 [8037405.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] Crit Rev Oncog. 2006 Jul;12(1-2):27-39 [17078205.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2195-8 [17522404.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5473-7 [9850081.001]
  • (PMID = 18230181.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P50 CA127003
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC2257954
  •  go-up   go-down


47. Agabiti E, Loganathan A, Rimmer M, Eames RA, Cullen PT: Cancer of ileostomy: a late complication of colectomy for ulcerative colitis. Acta Chir Belg; 2005 Feb;105(1):99-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of adenocarcinoma of the mucocutaneous junction at the ileostomy site, occurring 31 years after total colectomy for ulcerative colitis.
  • Wide excision of the moderately differentiated adenocarcinoma was performed with refashioning of the ileostomy.
  • Polypoid adenomas or adenocarcinomas of the ileostomy after colectomy performed for non-neoplastic conditions are extremely uncommon.
  • [MeSH-major] Adenocarcinoma / etiology. Colectomy / adverse effects. Colitis, Ulcerative / surgery. Ileal Neoplasms / etiology. Ileostomy / adverse effects


48. Kondo E, Miyake T, Shibata M, Kimura T, Iwagaki H, Nakamura S, Tanaka T, Ohara N, Ichimura K, Oka T, Yanai H, Shibasaki F, Yoshino T: Expression of phosphorylated Ser70 of Bcl-2 correlates with malignancy in human colorectal neoplasms. Clin Cancer Res; 2005 Oct 15;11(20):7255-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To elucidate this question that may suggest the biological role, we molecularly screened a panel of human colorectal adenomas and adenocarcinomas for endogenous expression of pSer70 Bcl-2.
  • EXPERIMENTAL DESIGN: An antibody specific against pSer70 Bcl-2 was generated for thorough immunohistochemical examination of paraffin-embedded tumor specimens, allowing detection of the endogenously expressed antigen among a range of Bcl-2-positive colorectal neoplasms, including 75 tubular adenomas, 114 adenocarcinomas, and 15 cases of cancer in adenomas.
  • RESULTS: Loss of pSer70 Bcl-2 expression was observed in adenocarcinomas in a differentiation-dependent manner (positivities: well differentiated 63%, moderately differentiated 52%, and poorly differentiated 12%), whereas tubular adenomas maintained their expression (positivity 88%).
  • Interestingly, an inverse correlation was found between expression of pSer70 Bcl-2 and Ki-67 antigen in those cases of cancer in adenoma (P < 0.01).
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243795.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 452VLY9402 / Serine
  •  go-up   go-down


49. Kuno T, Yokohira M, Matsuda Y, Suzuki S, Hashimoto N, Yamakawa K, Saoo K, Imaida K: Lack of modifying potential of 8-methoxypsoralen in the promotion or progression stages of lung carcinogenesis in A/J female mice. Oncol Rep; 2008 Oct;20(4):767-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since it has been reported that CYP2A protein is highly expressed in NNK-induced lung adenomas and adenocarcinomas, potential anticancer properties of 8-MOP in female A/J mice were examined subsequent to initiation.
  • On immunohistochemical analysis, the CYP2A protein was found to be overexpressed in all lung adenomas and adenocarcinomas, with or without 8-MOP.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. 8-METHOXYPSORALEN .
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813816.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CYP2A6 protein, human; 0 / Enzyme Inhibitors; 0 / Nitrosamines; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; EC 1.14.13.- / Cytochrome P-450 CYP2A6; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp2a5 protein, mouse; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


50. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Sueda T: Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg; 2007 Mar;11(3):338-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-two IPMNs, which consisted of 29 adenomas, 10 borderline tumors, 11 adenocarcinomas in situ, and invasive adenocarcinomas were reviewed from 1990 to 2003.
  • There was no recurrent disease in patients with adenoma and adenocarcinoma in situ, whereas recurrences occurred in 6 of 12 patients with invasive IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458608.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Katsube T, Konnno S, Hamaguchi K, Shimakawa T, Naritaka Y, Ogawa K, Aiba M: The efficacy of endoscopic mucosal resection in the diagnosis and treatment of group III gastric lesions. Anticancer Res; 2005 Sep-Oct;25(5):3513-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final diagnosis after EMR broadly classified the lesions as adenocarcinoma or adenoma.
  • RESULTS: Adenocarcinoma was identified in 16 patients (37.2%) and adenoma in 27 patients (62.8%).
  • A significant difference in the maximum diameter of elevated lesions (p<0.05) was found between adenocarcinomas and adenomas, with the elevated lesions of adenocarcinomas measuring more than 10 mm.
  • No residual focus recurrence was found among the adenomas.
  • [MeSH-major] Adenocarcinoma / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Aged. Biopsy. Endoscopy, Gastrointestinal. Female. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Humans. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101171.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


52. Brouland JP, Gélébart P, Kovàcs T, Enouf J, Grossmann J, Papp B: The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am J Pathol; 2005 Jul;167(1):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better characterize the role of SERCA3 in colon carcinogenesis, its expression has been investigated in colonic epithelium, benign lesions, adenomas, and adenocarcinomas.
  • We report that SERCA3 expression increased along the crypts as cells differentiated in normal colonic mucosa and in hyperplastic polyps, was moderately and heterogeneously expressed in colonic adenomas with expression levels inversely correlated with the degree of dysplasia, was barely detectable in well and moderately differentiated adenocarcinomas, and was absent in poorly differentiated tumors.
  • These data link SERCA3 expression to the state of differentiation of colonic epithelial cells, and relate SERCA3 expression, already decreased in adenomas, to enhanced adenomatous polyposis coli/beta-catenin/TCF4-dependent signaling and deficient Sp1-like factor-dependent transcription.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4395-405 [10361138.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):82-92 [10384103.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5523-6 [7923189.001]
  • [Cites] Gene. 1999 Nov 29;240(2):261-7 [10580145.001]
  • [Cites] J Biol Chem. 1992 Jul 15;267(20):14483-9 [1385815.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):G371-9 [1415549.001]
  • [Cites] Cell Calcium. 1993 Jul;14(7):531-8 [8402836.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2916-21 [7504695.001]
  • [Cites] Am J Med Sci. 1994 Mar;307(3):167-72 [8160706.001]
  • [Cites] J Mol Recognit. 1994 Sep;7(3):189-97 [7880543.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1468-74 [7557127.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6 [8629105.001]
  • [Cites] Biosci Rep. 1995 Oct;15(5):299-306 [8825032.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10746-50 [9099725.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22199-206 [9268365.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Cytokines Mol Ther. 1996 Jun;2(2):111-4 [9384695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1371-6 [10625687.001]
  • [Cites] Ann N Y Acad Sci. 1999;886:195-9 [10667218.001]
  • [Cites] Science. 2000 Apr 14;288(5464):331-3 [10764645.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] FEBS Lett. 2000 Jul 7;476(3):203-7 [10913614.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):926-9 [10963297.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):795-804 [10996197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G806-14 [11005769.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1291-7 [11100335.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):570-6 [11212251.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2413-22 [11259590.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):329-42 [11308031.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25742-52 [11337508.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):249-56 [11812948.001]
  • [Cites] FEBS Lett. 2002 Mar 13;514(2-3):122-8 [11943137.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16673-81 [11872750.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26310-20 [11986315.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):307-15 [12123752.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36471-8 [12119294.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):147-52 [12387883.001]
  • [Cites] Diabetes. 2002 Nov;51(11):3245-53 [12401716.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45579-91 [12207029.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):269-78 [12543089.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):279-305 [12543090.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):405-11 [12543099.001]
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):665-77 [12581631.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):107-17 [12633551.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3220-8 [12515718.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1861-2 [12692187.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):445-54 [12729578.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17785-91 [12624107.001]
  • [Cites] J Mol Endocrinol. 2003 Jun;30(3):399-409 [12790808.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6023-31 [12955081.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47877-89 [12975374.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] Nat Cell Biol. 2003 Dec;5(12):1041-3 [14647298.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):235-43 [15047174.001]
  • [Cites] Curr Mol Med. 2004 May;4(3):313-22 [15101688.001]
  • [Cites] Annu Rev Biochem. 2004;73:437-65 [15189149.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1223-36 [15336970.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Gastroenterology. 1974 Mar;66(3):347-56 [4813500.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):687-98 [6476197.001]
  • [Cites] Am J Med Sci. 1987 Nov;294(5):388-94 [2962490.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1988 Jul;51(4):746-51 [3144112.001]
  • [Cites] Nucleic Acids Res. 1989 Jul 25;17(14):5447-59 [2548163.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2483-92 [1702327.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13982-94 [9593748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9855-60 [9707565.001]
  • [Cites] Biochim Biophys Acta. 1999 Jan 18;1444(1):85-91 [9931450.001]
  • [Cites] Nutr Rev. 1999 Apr;57(4):124-6 [10228349.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):779-85 [10353711.001]
  • (PMID = 15972967.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Trans-Activators; 0 / Transcription Factor 7-Like 2 Protein; 0 / Transcription Factors; 0 / beta Catenin; EC 3.6.3.8 / ATP2A3 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1603437
  •  go-up   go-down


53. Yamada T, Obo Y, Furukawa M, Hotta M, Yamasaki A, Honoki K, Fukushima N, Tsujiuchi T: Mutations of lysophosphatidic acid receptor-1 gene during progression of lung tumors in rats. Biochem Biophys Res Commun; 2009 Jan 16;378(3):424-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No LPA1 mutations were detected in 15 hyperplasias, but 2 out of 12 adenomas (16.7%) and 7 out of 17 adenocarcinomas (41.2%).
  • These results suggest that mutations of LPA1 gene may be involved in the acquisition of growth advantage from adenomas to adenocarcinomas in lung carcinogenesis induced in rats by BHP.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Transformation, Neoplastic / genetics. Lung Neoplasms / genetics. Receptors, Lysophosphatidic Acid / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19026987.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 0 / Receptors, Lysophosphatidic Acid; 53609-64-6 / diisopropanolnitrosamine
  •  go-up   go-down


54. Zhang W, Hart J, McLeod HL, Wang HL: Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol; 2005 Jul;124(1):11-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We immunohistochemically examined 75 human colorectal neoplasms (adenoma, 27; adenocarcinoma, 24; neuroendocrine carcinoma, 24) for the expression of activator protein (AP)-1 family proteins.
  • Nuclear and cytoplasmic expression levels of c-Jun and Fra-1 proteins were markedly elevated in adenomas, adenocarcinomas and neuroendocrine carcinomas compared with nonneoplastic colorectal epithelial cells.
  • Overexpression of Fra-2 was evident in carcinomas but less frequent in adenomas.
  • Neuroendocrine carcinomas exhibited an AP-1 expression profile similar to adenocarcinomas except for infrequent overexpression of c-Jun in poorly differentiated variants.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Aged. Aged, 80 and over. Cluster Analysis. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins c-fos / biosynthesis. Proto-Oncogene Proteins c-jun / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923159.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM63340
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factor AP-1; 0 / fos-related antigen 1
  •  go-up   go-down


55. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, Fang JY: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia; 2008 Mar;10(3):287-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, immunohistochemical staining reveals that nuclear staining of phospho-STAT3 mostly presents in adenomas and adenocarcinomas, and a positive correlation is found between phospho-JAK2 immunoreactivity and the differentiation of colorectal adenocarcinomas.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):257-70 [15713897.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):833-8 [16049285.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6406-17 [16007195.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1184-91 [16489072.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3162-8 [16540667.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1445-51 [16685378.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2668-70 [16963263.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):224-33 [16819511.001]
  • [Cites] J Clin Pathol. 2007 Feb;60(2):173-9 [17264243.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1123-32 [17317820.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1577-85 [16953222.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2497-507 [17363567.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2517-25 [17363569.001]
  • [Cites] Leukemia. 2007 Apr;21(4):780-7 [17375124.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):12249-59 [17307743.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4940-8 [17510424.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3654-60 [17530019.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5389-96 [17545620.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5112-21 [17332240.001]
  • [Cites] Gut. 2007 Sep;56(9):1257-65 [17449633.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] Science. 2000 Jan 7;287(5450):142-4 [10615050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5405-10 [10792035.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):10-24 [10862190.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1543-8 [11171987.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):327-34 [11310826.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17397-405 [11859072.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6659-66 [12438264.001]
  • [Cites] Oncogene. 2003 Jan 30;22(4):548-54 [12555068.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):894-905 [12584569.001]
  • [Cites] Oncogene. 2003 Mar 20;22(11):1638-52 [12642867.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1270-9 [12649187.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5399-407 [12934099.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50402-11 [14523021.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1569-73 [15162527.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6109-18 [15342394.001]
  • [Cites] Science. 1995 Jul 7;269(5220):81-3 [7541555.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • (PMID = 18320073.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cysteine Proteinase Inhibitors; 0 / Leupeptins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / Tyrphostins; 0 / Vascular Endothelial Growth Factor A; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.10.2 / PTK2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2259457
  •  go-up   go-down


56. Uchiyama Y, Imazu H, Kakutani H, Hino S, Sumiyama K, Kuramochi A, Tsukinaga S, Matsunaga K, Nakayoshi T, Goda K, Saito S, Kaise M, Kawamuara M, Omar S, Tajiri H: New approach to diagnosing ampullary tumors by magnifying endoscopy combined with a narrow-band imaging system. J Gastroenterol; 2006 May;41(5):483-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All adenomas and adenocarcinomas had type II and/or type III surface structures, and patients whose ampulla had a type I surface structure had only inflammatory or hyperplastic changes.
  • In addition, abnormal vessels were seen only in adenocarcinomas and never in adenomas.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Aged. Biopsy. Female. Follow-Up Studies. Humans. Inflammation. Male. Microscopy, Video. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799891.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


57. Goere D, Elias D: [Appendiceal tumors found at appendectomy]. J Chir (Paris); 2009 Oct;146 Spec No 1:36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are three main histologic types of appendiceal tumor: adenoma, adenocarcinoma, and neuroendocrine tumor.
  • Adenomas and adenocarcinomas are both rare; they share two particularities: (a) a mucinous component is both frequent and predominant, (b) they have a tendency to intraperitoneal dissemination.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adenoma / diagnosis. Adenoma / surgery. Humans. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / surgery. Peritoneal Neoplasms / prevention & control. Pseudomyxoma Peritonei / prevention & control. Rupture / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846099.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 7
  •  go-up   go-down


58. Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, Stain S, Chapman WC, Washington MK, Willis J, Markowitz SD, Grady WM: CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer; 2006 Aug;45(8):781-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer.
  • Genetic alterations occur during the adenoma-carcinoma sequence of colon cancer formation and drive the initiation and progression of colon cancer formation.
  • Consequently, we assessed the frequency of gene methylation in tumors representative of the commonly recognized histological steps of the adenoma-carcinoma progression sequence through the analysis of eight genes previously identified to be methylated in colon cancer, MGMT, HLTF, MLH1, p14(ARF), CDKN2A, TIMP3, THBS1, and CDH1.
  • We observed that the proportion of tumors carrying methylated alleles increased from adenomas to adenocarcinomas but that the proportion of tumors with methylated alleles was not different between adenocarcinomas and metastases (69% versus 90%, P = 0.01 and 90% versus 81%, P > 0.05).
  • The most substantial difference occurred between early and advanced adenomas (47% versus 84%, P = 0.018).
  • Thus, the aberrant methylation of genes appears to increase most significantly during the progression of early adenomas to advanced adenomas, and the frequency of specific gene methylation at the different steps of the adenoma-carcinoma progression sequence varies in a gene-specific fashion.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. CpG Islands / genetics. DNA Methylation. Genes, Neoplasm


59. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol; 2005 Aug;58(8):833-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
  • AIMS: To examine the relation between p-STAT3 (activated form of STAT3) expression and clinicopathological factors in human colorectal adenocarcinoma and adenoma.
  • METHODS: Immunohistochemical analyses were carried out on tissues from 44 colorectal adenomas and 95 colorectal adenocarcinomas, comprising 18 intramucosal carcinomas and 77 invasive carcinomas.
  • Only eight of the 44 adenomas showed immunopositivity for p-STAT3, resulting in a significant difference between total adenocarcinomas and adenomas (p < 0.001).
  • Among the 95 cases of colorectal adenocarcinoma, p-STAT3 immunoreactivity was significantly correlated with the depth of tumour invasion (p < 0.05), venous invasion (p < 0.05), lymph node metastasis (p < 0.05), and increasing stages of the Dukes' classification (p < 0.01).
  • These findings suggest that p-STAT3 expression is an important factor related to carcinogenesis and/or tumour invasion of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 Apr 15;73(8):2076-82 [8156513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4806-10 [7545930.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1285-90 [7992833.001]
  • [Cites] Cancer Lett. 2000 Apr 3;151(1):31-8 [10766420.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2607-11 [10851059.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):67-73 [11006034.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):230-41 [11281168.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] Cancer. 2002 May 1;94(9):2393-400 [12015764.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1517-27 [12629515.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):891-905 [12949733.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):209-22 [14603523.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):15114-23 [14701810.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3550-60 [15116091.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1569-73 [15162527.001]
  • [Cites] Br J Surg. 1976 May;63(5):384-8 [1268479.001]
  • [Cites] Histopathology. 1981 Mar;5(2):141-63 [7216178.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1340-5 [3742458.001]
  • [Cites] Science. 1994 Apr 1;264(5155):95-8 [8140422.001]
  • [Cites] Cytokine. 1995 Feb;7(2):118-29 [7780031.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):591-4 [7566171.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3651-8 [8670868.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):600-4 [9263538.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):433-42 [9711905.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):326-30 [9766567.001]
  • [Cites] J Leukoc Biol. 1998 Nov;64(5):675-80 [9823774.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Jpn J Cancer Res. 1998 Dec;89(12):1267-75 [10081487.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] J Clin Pathol. 1949 May;2(2):95-8 [16810849.001]
  • (PMID = 16049285.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC1770863
  •  go-up   go-down


60. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • Fifty patients (40 with retained function of gallbladder and 10 patients with cholecystectomy) histologically diagnosed as proximal colon adenoma or adenocarcinoma were included into the study.
  • Colonoscopic biopsies have been taken from the lesion in cancer patients, and colonoscopic polypectomy has been performed for adenomas.
  • No significant difference was detected in the comparison of Ki-67 expression levels between the healthy mucosa and adenomas at the patients with cholecystectomy 43,4 +/- 3,45 (p > 0,05), but more prominent increase was revealed in adenocarcinomas 64,33 +/- 7,67% (p < 0,01).
  • At the patients without cholecystectomy the frequency of revealing p53 in adenomas does not vary, compared with healthy mucosa, however in adenocarcinomas p53 was not revealed at none case.
  • As a contrast, in group of the patients with cholecystectomy the frequency of revealing p53 in adenomas is considerably increased (up to 80%), and even in adenocarcinomas, p53 was revealed in 30,8% of cases.
  • At the patients with a cholecystectomy, the increase of proliferative activity is accompanied by increased apoptosis in adenomas and maintained apoptosis in adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


61. Kim SJ, Lee HW, Kim DC, Rha SH, Hong SH, Jeong JS: Significance of GLUT1 expression in adenocarcinoma and adenoma of the ampulla of Vater. Pathol Int; 2008 Apr;58(4):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of GLUT1 expression in adenocarcinoma and adenoma of the ampulla of Vater.
  • Twenty-one (58.3%) of 36 adenocarcinomas and three (17.6%) of 17 adenomas had GLUT1 immunoreactivity.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Ampulla of Vater / metabolism. Common Bile Duct Neoplasms / metabolism. Glucose Transporter Type 1 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324916.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human
  •  go-up   go-down


62. Brosens LA, Keller JJ, Pohjola L, Haglund C, Morsink FH, Iacobuzio-Donahue C, Goggins M, Giardiello FM, Ristimäki A, Offerhaus GJ: Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther; 2008 Mar;7(3):424-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate expression of HuR in the colorectal adenoma-carcinoma sequence, we examined expression of HuR in colorectal mucosa of patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer with correlation to COX-2 expression.
  • RESULTS: Cytoplasmic HuR staining was found in the epithelium of 10% of normal mucosa, 14.3% of adenomas and 88.9% of adenocarcinomas from FAP patients (p < 0.01) and in 68.8% of sporadic colorectal carcinomas.
  • High epithelial COX-2 immunostaining was observed in 10% of normal, 8% of adenomas and all adenocarcinomas from FAP patients (p < 0.01) and in 69.5% of sporadic colorectal carcinomas.
  • Positive cytoplasmic HuR immunostaining correlated with high COX-2 immunoreactivity in colon mucosa of FAP patients (p < 0.01) and in sporadic colorectal carcinomas. (p = 0.016) MATERIALS AND METHODS: HuR and COX-2 protein expression were studied by immunohistochemistry of normal colon mucosa (N=20), adenomas (N=112), carcinomas (N=9) from patients with FAP, and 141 sporadic colorectal adenocarcinomas (Dukes B and C).
  • CONCLUSIONS: HuR is increasingly expressed in the cytoplasmic epithelial compartment in consecutive stages of the adenoma-carcinoma sequence in FAP.
  • The role of cytoplasmic expression of HuR as a biomarker for progression of adenomas in FAP needs further study.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2008 Mar;7(3):428-9 [18285701.001]
  • (PMID = 18094611.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 53801; United States / NCI NIH HHS / CA / CA51085; United States / NCI NIH HHS / CA / CA63721; United States / NCI NIH HHS / CA / P50 CA 93-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / Phosphoproteins; 0 / RNA-Binding Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


63. Guan J, Chen J, Luo YF, Cao JL, Zhao H, Hao J: [Expression of survivin in colorectal adenoma and adenocarcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Jun;29(3):398-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin in colorectal adenoma and adenocarcinoma].
  • METHODS Immunohistochemistry staining was performed by two-step EnVision technique for the paraffin sections, which included 90 adenomas, 25 ademomas with high-grade glandular intraepithelial neoplasia, and 108 colorectal adenocarcinomas.
  • The positive rate of SVV in tubular adenomas, villous adenomas, and tubulovillous adenomas were 30% (12/40), 40.9% (9/22), and 35.8% (10/28), respectively.
  • The positive rate of SVV in tubulovillous adenomas with high-grade glandular intraepithelial neoplasia were 68% (17/25).
  • SVV expressions among the three types of adenomas without neoplasia were not significantly different (P > 0.05).
  • SVV expression between each type of the above-mentioned ademoma and tubulovillous adenoma with high-grade glandular intraepithelial neoplasia or different Dukes stages of colorectal carcinoma was significantly different (P < 0.05).
  • SVV expressions in adenocarcinomas and adenomas with high grade glandular intraepithelial neoplasia were significantly higher than those in adenomas (P < 0.01).
  • SVV expression may be useful to distinguish adenocarcinoma from adenoma in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Microtubule-Associated Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633470.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


64. Groff RJ, Nash R, Ahnen DJ: Significance of serrated polyps of the colon. Curr Gastroenterol Rep; 2008 Oct;10(5):490-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The fundamental view that colon adenocarcinomas arise only from conventional adenomas has been challenged by the now recognized hyperplastic polyp-serrated adenoma-adenocarcinoma pathway.
  • This article describes the history of the serrated adenoma (both the traditional serrated adenoma and the sessile serrated adenoma) as well as the histology and endoscopic appearance of these lesions in comparison with hyperplastic polyps and mixed polyps.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2711-6 [17227517.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2866-77 [17227527.001]
  • [Cites] Gastrointest Endosc. 2007 May;65(6):757-66 [17466195.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):440-5 [17516746.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):947-68, viii [17996799.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):30-5 [18162767.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):25-46, v [18313538.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1027-35 [18319413.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1141-7 [10810411.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):827-30 [11221863.001]
  • [Cites] J Pathol. 2001 Mar;193(3):286-94 [11241406.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1296-308 [12094842.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Pathology. 2002 Dec;34(6):548-55 [12555993.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):705-8 [12598303.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] Mod Pathol. 2003 May;16(5):417-23 [12748247.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):778-96 [12817424.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):736-42 [10343219.001]
  • [Cites] Am J Gastroenterol. 2004 Nov;99(11):2242-55 [15555008.001]
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):349-59 [15716230.001]
  • [Cites] Endoscopy. 2005 Mar;37(3):254-60 [15731942.001]
  • [Cites] Arch Intern Med. 2005 Feb 28;165(4):382-90 [15738366.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):385-91 [15758908.001]
  • [Cites] Histopathology. 2005 Jul;47(1):32-40 [15982321.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] World J Gastroenterol. 2006 May 7;12(17):2770-2 [16718767.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1400-7 [17101316.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):423-34 [15087661.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Dis Colon Rectum. 1979 Apr;22(3):152-6 [446245.001]
  • [Cites] Am J Surg Pathol. 1984 Jul;8(7):551-6 [6742315.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Pathology. 1992 Oct;24(4):233-42 [1289763.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):423-9 [9247459.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5 [9618505.001]
  • (PMID = 18799125.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA068099-09S1; United States / NCI NIH HHS / CA / R01 CA068099-09S1
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  • [Other-IDs] NLM/ NIHMS210910; NLM/ PMC3437745
  •  go-up   go-down


65. Fukuyama M, Rokutan K, Sano T, Miyake H, Shimada M, Tashiro S: Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon. Cancer Lett; 2005 Apr 18;221(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon.
  • Adenomas and well differentiated adenocarcinomas up-regulated Nox1 expression.
  • Nuclear factor (NF)-kappaB was predominantly activated in adenoma and adenocarcinoma cells expressing abundant Nox1, suggesting that Nox1 may stimulate NF-kappaB-dependent antiapoptotic pathways in colon tumors.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Colonic Neoplasms / enzymology. NADPH Oxidase / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797632.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / NF-kappa B; EC 1.6.3.- / NOX1 protein, human; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


66. Noguera Aguilar JF, Amengual Antich I, Plaza Martínez A, Ibarra de la Rosa J, Tortajada Collado C, Gamundí Gamundí A, Pujol Tugores JJ: Cyclooxygenase-2 inhibition in colon experimental carcinogenesis. Rev Esp Enferm Dig; 2005 Sep;97(9):637-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rofecoxib in lower doses had the same effect on adenomas (p < 0.05) with no effect on adenocarcinomas.
  • Rofecoxib reduced COX-2 expression in tumoral tissue from adenomas and adenocarcinomas (p < 0.01).
  • CONCLUSIONS: Rofecoxib prevents chemical colon carcinogenesis in the rat, with a reduction of tumoral colonic percentage in adenocarcinomas and tumoral COX-2 expression.

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266236.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; EC 1.14.99.1 / Cyclooxygenase 2; IX068S9745 / 1,2-Dimethylhydrazine; R16CO5Y76E / Aspirin
  •  go-up   go-down


67. Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem; 2010 Mar;58(3):277-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24A1) is considered to be the main enzyme determining the biological half-life of 1,25-D(3), we have examined expression of the CYP24A1 mRNA (by real-time RT-PCR) and protein (by immunohistochemistry) in normal human colon mucosa, colorectal adenomas, and adenocarcinomas in 111 patients.
  • Although 76% of the normal and benign colonic tissue was either completely devoid of or expressed very low levels of CYP24A1, in the majority of the adenocarcinomas (69%), the enzyme was present at high concentrations.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / enzymology. Steroid Hydroxylases / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem. 2000 May;127(5):717-22 [10788778.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1581-9 [15905206.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6158-65 [11012668.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):847-52 [11075874.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):888-94 [11158062.001]
  • [Cites] Steroids. 2001 Mar-May;66(3-5):409-22 [11179750.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):1043-51 [11309356.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 27;285(4):1012-7 [11467853.001]
  • [Cites] Occup Environ Med. 2002 Apr;59(4):257-62 [11934953.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1583-8 [12352462.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):31-41 [16145679.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):179-94 [16236494.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(2):234-40 [16180015.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1424-33 [16247453.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):415-24 [16556015.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2687-99 [16886679.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1819-28 [16708384.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Mar;320(3):1119-26 [17182978.001]
  • [Cites] J Mol Med (Berl). 2007 Mar;85(3):293-304 [17143621.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):684-700 [17721433.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1257-64 [17875655.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3131-8 [18089708.001]
  • [Cites] Curr Med Res Opin. 2008 Jan;24(1):139-49 [18034918.001]
  • [Cites] Mol Aspects Med. 2008 Dec;29(6):388-96 [18755215.001]
  • [Cites] Recent Results Cancer Res. 2003;164:239-46 [12899526.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):38084-93 [12867411.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):236-41 [14760115.001]
  • [Cites] J Cutan Pathol. 2004 Mar;31(3):224-31 [14984574.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):693-702 [15077124.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):985-9 [15208365.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Steroids. 1990 Sep;55(9):395-8 [2281516.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):24673-8 [7929139.001]
  • [Cites] J Invest Dermatol. 1997 Apr;108(4):513-8 [9077483.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 May;62(1):21-8 [9366495.001]
  • [Cites] Endocrinology. 1999 May;140(5):2071-6 [10218956.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):82-90 [10337990.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3579-86 [15867263.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20604-11 [15788398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7 [16103450.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 14;273(3):977-84 [10891358.001]
  • (PMID = 19901270.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Receptors, Calcitriol; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / CYP24A1 protein, human; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  • [Other-IDs] NLM/ PMC2825493
  •  go-up   go-down


68. Remy L, Trespeuch C, Bachy S, Scoazec JY, Rousselle P: Matrilysin 1 influences colon carcinoma cell migration by cleavage of the laminin-5 beta3 chain. Cancer Res; 2006 Dec 1;66(23):11228-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This enzyme is generally not expressed by normal differentiated epithelial colon cells, but has been shown to be up-regulated in human colon adenomas and adenocarcinomas.
  • In this study, we show that LN5 and MMP7 are coexpressed in HT29 cells as well as in HT29 xenograft tumors and human colorectal adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Amino Acid Sequence. Animals. Animals, Newborn. Blotting, Western. Gene Expression Regulation, Neoplastic. HT29 Cells. Humans. Molecular Sequence Data. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145868.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / kalinin; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


69. Oyama T, Yasui Y, Sugie S, Koketsu M, Watanabe K, Tanaka T: Dietary tricin suppresses inflammation-related colon carcinogenesis in male Crj: CD-1 mice. Cancer Prev Res (Phila); 2009 Dec;2(12):1031-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of colonic adenomas and adenocarcinomas was significantly reduced by feeding with 50 and 250 ppm tricin, respectively.
  • Dietary tricin also significantly reduced the proliferation of adenocarcinoma cells as well as the numbers of mitoses/anaphase bridging in adenocarcinoma cells.
  • Our findings that dietary tricin inhibits inflammation-related mouse colon carcinogenesis by suppressing the expression of TNF-alpha in the nonlesional cyrpts and the proliferation of adenocarcinomas suggest a potential use of tricin for clinical trials of colorectal cancer chemoprevention.
  • [MeSH-major] Adenocarcinoma / prevention & control. Adenoma / prevention & control. Colonic Neoplasms / prevention & control. Diet. Flavonoids / administration & dosage. Inflammation / prevention & control. Phytotherapy

  • MedlinePlus Health Information. consumer health - Diets.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934339.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Flavonoids; 0 / Plant Extracts; 0 / RNA, Messenger; D51JZL38TQ / tricin; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


70. Takizawa T, Imai T, Ueda M, Onodera H, Hirose M: Comparison of enhancing effects of different goitrogen treatments in combination with beta-estradiol-3-benzoate for establishing a rat two-stage thyroid carcinogenesis model to detect modifying effects of estrogenic compounds. Cancer Sci; 2006 Jan;97(1):25-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the long-term experiment after DHPN initiation, EB alone slightly increased small numbers of animals with follicular hyperplasias, adenomas and adenocarcinomas.
  • Simultaneous treatment with antithyroidal chemicals was associated with an increase in the incidences of focal hyperplasias, adenomas and/or adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2005).
  • (PMID = 16367917.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithyroid Agents; 0 / Estrogens; 0 / Proliferating Cell Nuclear Antigen; 1S4CJB5ZGN / estradiol 3-benzoate; 4TI98Z838E / Estradiol
  •  go-up   go-down


71. Hochwartner O, Loupal G, Wildgoose WH, Schmidt-Posthaus H: Occurrence of spontaneous tumours of the renal proximal tubules in oscars Astronotus ocellatus. Dis Aquat Organ; 2010 Mar 9;89(2):185-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report describes the occurrence of renal papillary cystic adenomas and adenocarcinomas in oscars Astronotus ocellatus Cuvier, 1829.
  • [MeSH-major] Adenoma / veterinary. Cichlids. Fish Diseases / pathology. Kidney Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402236.001).
  • [ISSN] 0177-5103
  • [Journal-full-title] Diseases of aquatic organisms
  • [ISO-abbreviation] Dis. Aquat. Org.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Lu G, Liao J, Yang G, Reuhl KR, Hao X, Yang CS: Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res; 2006 Dec 01;66(23):11494-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine.
  • The present study investigated the inhibitory effects of Polyphenon E [a standardized green tea polyphenol preparation containing 65% (-)-epigallocatechin-3-gallate] and caffeine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumor progression from adenoma to adenocarcinoma.
  • Female A/J mice were treated with a single dose of NNK (103 mg/kg body weight, i.p.) and kept for 20 weeks for the mice to develop lung adenomas.
  • Histopathologic analysis indicated that Polyphenon E administration significantly reduced the incidence (by 52%) and multiplicity (by 63%) of lung adenocarcinoma.
  • Caffeine also showed marginal inhibitory effects in incidence and multiplicity of adenocarcinoma (by 48% and 49%, respectively).
  • Polyphenon E and caffeine treatment inhibited cell proliferation (by 57% and 50%, respectively) in adenocarcinomas, enhanced apoptosis in adenocarcinomas (by 2.6- and 4-fold, respectively) and adenomas (both by 2.5-fold), and lowered levels of c-Jun and extracellular signal-regulated kinase (Erk) 1/2 phosphorylation.
  • The results show that tea polyphenols (and perhaps caffeine) inhibit the progression of NNK-induced lung adenoma to adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / prevention & control. Adenoma / prevention & control. Caffeine / therapeutic use. Flavonoids / therapeutic use. Lung Neoplasms / prevention & control. Phenols / therapeutic use. Tea / chemistry

  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145898.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA72720; United States / NCI NIH HHS / CA / CA88961; United States / NIEHS NIH HHS / ES / ES50522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Nitrosamines; 0 / Phenols; 0 / Polyphenols; 0 / Proliferating Cell Nuclear Antigen; 0 / Tea; 0 / polyphenon E; 3G6A5W338E / Caffeine; 7S395EDO61 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 8R1V1STN48 / Catechin; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


73. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA: A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science; 2009 Mar 27;323(5922):1747-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the offspring developed intestinal lesions, including intraepithelial neoplasia, adenomas, and adenocarcinomas.


74. Lü K, Dai Q, Xu ZH, Zhang YX, Tan L, Yuan Y, Jiang YX: Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas. Chin Med Sci J; 2010 Sep;25(3):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twelve patients with IPMN underwent surgery between May 2005 and December 2008, including 4 (33.3%) with adenoma and 8 (66.7%) with adenocarcinoma.
  • The mean diameters of the lesions were 1.4 +/- 0.8 cm (range, 0.5-2.0) and 6.3 +/- 6.0 cm (range, 2.0-20.0) in adenomas and adenocarcinomas, respectively.
  • And the mean diameters of the main duct in adenomas and adenocarcinomas were 1.0 +/- 0.8 cm and 1.6 +/- 1.0 cm, respectively.
  • Among the 8 adenocarcinomas, 5 (62.5%) cases were classified as main duct type, and 3 (37.5%) as combined type.
  • In 7 of the 8 adenocarcinomas, mural nodules were detected within the dilated ducts or cysts of the lesions in which color flow signals were detected.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180276.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


75. Liu JR, Sun XR, Dong HW, Sun CH, Sun WG, Chen BQ, Song YQ, Yang BF: beta-Ionone suppresses mammary carcinogenesis, proliferative activity and induces apoptosis in the mammary gland of the Sprague-Dawley rat. Int J Cancer; 2008 Jun 15;122(12):2689-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proportions of adenocarcinomas, adenomas and benign masses were equally distributed in the latter group.
  • In proportions within the other groups, the proportions of adenocarcinomas and benign masses decreased and increased with increasing dietary beta-ionone.

  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18386789.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Norisoprenoids; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 136601-57-5 / Cyclin D1; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; A7NRR1HLH6 / beta-ionone
  •  go-up   go-down


76. Funovics MA, Alencar H, Montet X, Weissleder R, Mahmood U: Simultaneous fluorescence imaging of protease expression and vascularity during murine colonoscopy for colonic lesion characterization. Gastrointest Endosc; 2006 Oct;64(4):589-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two mouse models were used (Apcmin(+/-) mice for colonic adenomas and CT26 murine colon cancer).
  • Both colonic adenomas and adenocarcinomas were clearly visible in the NIR channel on protease probe administration in live mice.
  • Ratio imaging of protease activity/perfusion increased from healthy colon to adenomas to adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / pathology. Adenoma / blood supply. Adenoma / pathology. Biomarkers, Tumor / analysis. Colonic Neoplasms / blood supply. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Colonoscopes. Dermoscopy / instrumentation. Image Interpretation, Computer-Assisted / instrumentation. Neoplasms, Experimental / blood supply. Neoplasms, Experimental / pathology. Peptide Hydrolases / analysis. Spectroscopy, Near-Infrared / instrumentation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996355.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB001872; United States / PHS HHS / / P50 C 86355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.- / Peptide Hydrolases; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


77. Wang Y, Zhang Z, Yao R, Jia D, Wang D, Lubet RA, You M: Prevention of lung cancer progression by bexarotene in mouse models. Oncogene; 2006 Mar 2;25(9):1320-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although all mice developed lung tumors, only 7% of lung tumors were adenocarcinomas in wild-type mice, whereas 22 and 26% of lung tumors were adenocarcinomas in p53 transgenic or K-ras heterozygous deficient mice.
  • Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by approximately 50% in both p53(wt/wt)K-ras(ko/wt) and p53(wt/wt)K-ras(wt/wt) mice.
  • [MeSH-major] Adenocarcinoma / prevention & control. Anticarcinogenic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / prevention & control. Lung Neoplasms / prevention & control. Tetrahydronaphthalenes / pharmacology
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Animals. Carcinogens / administration & dosage. Disease Models, Animal. Disease Progression. Genes, p53. Genes, ras. Humans. Mice. Mice, Transgenic. Urethane / administration & dosage. Urethane / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247446.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01CN25104; United States / NCI NIH HHS / CA / R01CA58554
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Tetrahydronaphthalenes; 3IN71E75Z5 / Urethane; 7Y2431GOM5 / vinyl carbamate; A61RXM4375 / bexarotene
  •  go-up   go-down


78. Perse M, Zebic A, Cerar A: Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer. Scand J Gastroenterol; 2005 Jan;40(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal tumours were evaluated quantitatively and histopathologically for the presence of aberrant crypt foci (ACF), adenomas and adenocarcinomas.
  • However, a significant lower incidence of adenomas (p < 0.05), adenocarcinomas (p < 0.05) and decreased volume of macroscopically visible tumours (by 42%) was found in the experimental group.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841716.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


79. Abiko K, Baba T, Ogawa M, Mikami Y, Koyama T, Mandai M, Konishi I: Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus. Pathol Int; 2010 Jan;60(1):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus.
  • Primary mucinous adenocarcinomas of the uterine corpus are typically low grade and frequently associated with endometrial hyperplasia and/or ordinary endometrioid adenocarcinoma, but may appear as a heterogeneous group of neoplasms.
  • Microscopic examination of hysterectomy specimens indicated highly differentiated mucinous adenocarcinoma diffusely infiltrating the portion of adenomyosis of the corpus.
  • HIK1083 and MUC6 immunohistochemistry indicated a gastric phenotype of the tumor, as seen in cases of prototypical minimal deviation adenocarcinoma (MDA) of the cervix.
  • In summary, mucinous endometrial adenocarcinoma rarely shows features similar to MDA of the cervix.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology


80. Suzui M, Inamine M, Kaneshiro T, Morioka T, Yoshimi N, Suzuki R, Kohno H, Tanaka T: Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis. Int J Oncol; 2005 Nov;27(5):1391-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used a long-term rat model by using azoxymethane (AOM) to induce tumors (adenomas and adenocarcinomas) in the colon.
  • In the present study, we found that after AOM injection, the treatment of male F344 rats with 0.01 and 0.05% I3C caused a significant increase in the tumor multiplicity of adenocarcinomas by 2.2- (P<0.05 for 0.01% I3C) and 2.1-fold (P<0.0002 for 0.05% I3C) respectively, when compared to the control rats.
  • In addition, the tumor multiplicity of adenoma plus adenocarcinoma and the volume of adenocarcinoma were also increased by 2.0- (P<0.00001) and 2.1-fold (P<0.05) respectively, compared to the control.
  • I3C significantly increased the proliferating cell nuclear antigen labeling index (PCNA LI) (P<0.008) and decreased the apoptotic index (P<0.05) of the colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Antioxidants / pharmacology. Colonic Neoplasms / pathology. Indoles / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211236.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Indoles; C11E72455F / indole-3-carbinol
  •  go-up   go-down


81. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Feb;16(2):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.
  • We investigated leptin expression in normal and neoplastic colorectal tissues and its association with clinicopathological features and clinical outcome in colorectal adenocarcinoma patients.
  • Leptin expression was evaluated on the tissue microarray of 44 normal colon mucosal tissues, 44 adenomatous polyps, and 437 colorectal adenocarcinomas by immunohistochemistry.
  • Frequency of leptin expression was dramatically increased from normal colonic mucosa (2/44, 4.5%) to adenomas (13/44, 29.5%) and adenocarcinomas (321/437, 73.5%) as neoplastic progression.
  • In univariate survival analysis, patients with leptin-positive adenocarcinoma revealed better overall and disease-free survivals (p = 0.032 and p = 0.004, respectively, log-rank test).
  • We conclude that leptin was gradually expressed during the normal-adenoma-adenocarcinoma sequence, suggesting an association in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Leptin / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Colon / metabolism. Colon / pathology. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Phenotype. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050975.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


82. Shi Z, Dragin N, Miller ML, Stringer KF, Johansson E, Chen J, Uno S, Gonzalez FJ, Rubio CA, Nebert DW: Oral benzo[a]pyrene-induced cancer: two distinct types in different target organs depend on the mouse Cyp1 genotype. Int J Cancer; 2010 Nov 15;127(10):2334-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyp1a1(-/-) mice revealed markedly increased CYP1B1 mRNA levels in the PSI, and between 8 and 12 weeks developed unique PSI adenomas and adenocarcinomas.
  • PSI adenocarcinomas exhibited striking upregulation of the Xist gene, suggesting epigenetic silencing of specific genes on the Y-chromosome; the Rab30 oncogene was upregulated; the Nr0b2 tumor suppressor gene was downregulated; paradoxical overexpression of numerous immunoglobulin kappa- and heavy-chain variable genes was found-although the adenocarcinoma showed no immunohistochemical evidence of being lymphatic in origin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D258-61 [14681407.001]
  • [Cites] Br Med Bull. 2003;68:167-82 [14757716.001]
  • [Cites] Mol Pharmacol. 2004 May;65(5):1225-37 [15102951.001]
  • [Cites] Biotechniques. 2004 May;36(5):790-6 [15152598.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23847-50 [15028720.001]
  • [Cites] Environ Health Perspect. 2004 Jun;112(9):970-8 [15198916.001]
  • [Cites] Mol Pharmacol. 1975 Nov;11(6):850-65 [54870.001]
  • [Cites] Cancer Res. 1978 Sep;38(9):2777-83 [679184.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Nov;75(11):5358-61 [281685.001]
  • [Cites] Biochem Pharmacol. 1979;28(1):149-51 [758905.001]
  • [Cites] J Natl Cancer Inst. 1981 May;66(5):913-7 [6262559.001]
  • [Cites] Drug Metab Rev. 1982;13(2):235-47 [6807663.001]
  • [Cites] Pharmacol Rev. 1982 Jun;34(2):189-222 [6287505.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):4875-917 [6814745.001]
  • [Cites] Carcinogenesis. 1983;4(5):513-7 [6850980.001]
  • [Cites] Environ Health Perspect. 1988 Apr;77:11-21 [3289903.001]
  • [Cites] Crit Rev Toxicol. 1989;20(3):153-74 [2558673.001]
  • [Cites] Am J Med. 1992 Jul 15;93(1A):13S-17S [1496998.001]
  • [Cites] Drug Metab Rev. 1994;26(1-2):125-63 [8082562.001]
  • [Cites] Nat Genet. 1996 Oct;14(2):128-9 [8841177.001]
  • [Cites] Carcinogenesis. 1998 Jan;19(1):117-24 [9472702.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1977-82 [10051580.001]
  • [Cites] Epigenetics. 2008 Sep;3(5):246-9 [19013827.001]
  • [Cites] J Cell Biol. 2008 Nov 17;183(4):607-15 [19001129.001]
  • [Cites] Mucosal Immunol. 2008 Nov;1(6):460-9 [19079213.001]
  • [Cites] J Biol Chem. 2008 Dec 26;283(52):36061-5 [18713746.001]
  • [Cites] Hum Genomics. 2008 Sep;3(1):87-97 [19129093.001]
  • [Cites] Bioinformatics. 2009 Jan 15;25(2):211-7 [19038984.001]
  • [Cites] Prog Histochem Cytochem. 2007;42(2):61-110 [17616258.001]
  • [Cites] Surg Today. 2007;37(9):725-34 [17713724.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] APMIS. 2007 Oct;115(10):1147-60 [18042148.001]
  • [Cites] Free Radic Biol Med. 2008 Feb 15;44(4):570-83 [17997381.001]
  • [Cites] J Allergy Clin Immunol. 2008 Feb;121(2 Suppl):S380-3; quiz S415 [18241686.001]
  • [Cites] Trends Endocrinol Metab. 2008 Mar;19(2):74-81 [18054496.001]
  • [Cites] Cancer Sci. 2008 May;99(5):849-55 [18380788.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Biol Chem. 2008 Apr;389(4):323-31 [18225988.001]
  • [Cites] Tissue Antigens. 2008 Jul;72(1):1-10 [18498291.001]
  • [Cites] Hepatology. 2008 Jul;48(1):289-98 [18537191.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] J Exp Med. 2008 Aug 4;205(8):1755-61 [18663129.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 17;100(18):1310-7 [18780863.001]
  • [Cites] Cell Mol Immunol. 2008 Oct;5(5):319-24 [18954554.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):2932-8 [16374581.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1103-14 [16377763.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4792-801 [14581350.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):225-32 [19153668.001]
  • [Cites] Cell Death Differ. 2008 Jul;15(7):1103-12 [18552861.001]
  • [Cites] Biochem Pharmacol. 2000 Jan 1;59(1):65-85 [10605936.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):184-9 [10623596.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1129-42 [11007951.001]
  • [Cites] Ann N Y Acad Sci. 2000;919:148-70 [11083106.001]
  • [Cites] Drug Metab Rev. 2001 Feb;33(1):1-35 [11270659.001]
  • [Cites] Carcinogenesis. 2001 Dec;22(12):1903-30 [11751421.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2733-40 [12529989.001]
  • [Cites] Bioinformatics. 2003 Feb 12;19(3):368-75 [12584122.001]
  • [Cites] Ind Health. 2003 Jul;41(3):127-38 [12916742.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):199-204 [10102353.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):2916-20 [16374579.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1625-32 [16863570.001]
  • [Cites] Exp Anim. 2006 Jul;55(4):343-7 [16880681.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):940-6 [17183066.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):661-3 [16837629.001]
  • (PMID = 20127859.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006096-149007; United States / NIEHS NIH HHS / ES / P30 ES006096-139007; United States / NIEHS NIH HHS / ES / ES006096-119007; United States / NIEHS NIH HHS / ES / ES014403-03; United States / NIEHS NIH HHS / ES / R01 ES014403-02; United States / NIEHS NIH HHS / ES / ES006096-159007; United States / NIEHS NIH HHS / ES / ES014403-02; United States / NIEHS NIH HHS / ES / ES006096-149007; United States / NIEHS NIH HHS / ES / R01 ES014403; United States / NIEHS NIH HHS / ES / R01 ES014403-04; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIEHS NIH HHS / ES / R01 ES014403-03S1; United States / NIEHS NIH HHS / ES / ES014403-03S1; United States / NIEHS NIH HHS / ES / P30 ES006096-159007; United States / NIEHS NIH HHS / ES / ES006096-139007; United States / NIEHS NIH HHS / ES / ES006096-129007; United States / NIEHS NIH HHS / ES / R01 ES014403-03; United States / NIEHS NIH HHS / ES / P30 ES006096-119007; United States / NIEHS NIH HHS / ES / P30 ES006096-129007; United States / NIEHS NIH HHS / ES / P30 ES06096
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 3417WMA06D / Benzo(a)pyrene; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp1b1 protein, mouse; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1
  • [Other-IDs] NLM/ NIHMS184552; NLM/ PMC2917638
  •  go-up   go-down


83. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS: Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology; 2010 Jan;56(2):229-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma.
  • METHODS AND RESULTS: Immunohistochemistry staining for PTEN was performed on a tissue microarray of 19 samples of normal colonic mucosa, 14 adenomatous polyps, 482 adenocarcinomas and 56 metastatic lymph nodes.
  • However, only 241 (50.0%) of the 482 colorectal adenocarcinomas and 26 (46.4%) of the 56 metastatic lymph nodes were positive for PTEN.
  • On univariate survival analysis, patients with PTEN- adenocarcinoma revealed a poor overall and disease-free survival (P = 0.030 and P = 0.046, respectively).
  • CONCLUSIONS: Nuclear PTEN expression gradually decrease during the normal-adenoma-adenocarcinoma-metastasis sequence, which suggests an important role for PTEN in carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenomatous Polyps / metabolism. Cell Nucleus / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. PTEN Phosphohydrolase / metabolism. Rectum / metabolism


84. Legler M, Kothe R, Rautenschlein S, Kummerfeld N: [Detection of psittacid herpesvirus 1 in Amazon parrots with cloacal papilloma (internal papillomatosis of parrots, IPP) in an aviary of different psittacine species]. Dtsch Tierarztl Wochenschr; 2008 Dec;115(12):461-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Macroscopical and histological investigation of amazons with cloacal prolaps revealed a papillomic adenoma of the cloacal mucosa accompanied by varying degrees of bile duct carcinomas in the liver and adenocarcinomas of the pancreas.
  • We may speculate that there is correlation between the infection with PsHV-1 and the development of cloacal adenomas, adenocarcinomas in the pancreas and carcinomas of the bile ducts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19113029.001).
  • [ISSN] 0341-6593
  • [Journal-full-title] DTW. Deutsche tierärztliche Wochenschrift
  • [ISO-abbreviation] DTW. Dtsch. Tierarztl. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. De Miglio MR, Virdis P, Calvisi DF, Mele D, Muroni MR, Frau M, Pinna F, Tomasi ML, Simile MM, Pascale RM, Feo F: Identification and chromosome mapping of loci predisposing to colorectal cancer that control Wnt/beta-catenin pathway and progression of early lesions in the rat. Carcinogenesis; 2007 Nov;28(11):2367-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we performed genome-wide scanning of male (ACI/SegHsd x Wistar-Furth)F2 (AWF2) rats to map susceptibility genes influencing the evolution of early colorectal lesions to adenocarcinoma following 1,2-dimethylhydrazine administration.
  • Phenotypic analysis revealed higher incidence/multiplicity and lower size of adenomas in ACI/SegHsd (ACI) and (ACI/SegHsd x Wistar-Furth)F1 (AWF1) than Wistar-Furth (WF) rats and higher incidence/multiplicity of poorly differentiated adenocarcinomas in WF than ACI rats, with intermediate values in AWF1 rats.
  • Seven other loci on chromosomes 5, 6, 15, 17, 18 and 20 were in suggestive linkage with adenoma/adenocarcinoma multiplicity/surface area.
  • However, influence of susceptibility/resistance genes on Wnt/beta-catenin pathway was shown by defective beta-catenin inactivation in WF but not in ACI and AWF1 rat adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • SciCrunch. RGD: Data: Animal Model .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510081.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / F32 AA020150
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


86. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM: Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol; 2007 Feb;170(2):693-708
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neutrophils infiltrated the alveoli of tumor-bearing lungs and within the periphery of macroscopic adenomas and adenocarcinomas.
  • These biochemical markers of macrophage activation states would have diagnostic and/or therapeutic value if analogous systemic shifts occur in humans.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2001 Jun;32(3):265-79 [11390008.001]
  • [Cites] J Histochem Cytochem. 2001 Aug;49(8):1061-2 [11457936.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Feb 10;124(3):615-29 [16469706.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):5023-32 [16585599.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1423-33 [11583970.001]
  • [Cites] Toxicology. 2001 Dec 1;169(1):1-15 [11696405.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Cell Prolif. 1999 Dec;32(6):351-61 [10646687.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):509-18 [10666380.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Feb 15;165(4):508-13 [11850344.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6850-6 [12460898.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Nat Rev Immunol. 2003 Jan;3(1):23-35 [12511873.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):186-98 [12539173.001]
  • [Cites] Clin Lung Cancer. 2003 Jul;5(1):46-62 [14596704.001]
  • [Cites] Cell Mol Life Sci. 2003 Nov;60(11):2334-46 [14625680.001]
  • [Cites] Novartis Found Symp. 2004;256:137-45; discussion 146-8, 259-69 [15027487.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3458-64 [15150098.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2053-8 [15164120.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1660-7 [15251154.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5084-8 [15289309.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • [Cites] J Cell Sci. 1966 Sep;1(3):297-310 [4291022.001]
  • [Cites] Int J Cancer. 1967 Jul 15;2(4):326-36 [6055972.001]
  • [Cites] Cancer Res. 1969 May;29(5):994-8 [5781107.001]
  • [Cites] J Natl Cancer Inst. 1983 May;70(5):931-6 [6573537.001]
  • [Cites] Immunology. 1984 Dec;53(4):753-67 [6389324.001]
  • [Cites] J Natl Cancer Inst. 1985 Nov;75(5):963-9 [3863993.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5335-8 [3756882.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):918-31 [2849325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3070-4 [2654935.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Immunol. 1992 Oct 15;149(8):2709-14 [1401910.001]
  • [Cites] N Engl J Med. 1993 Jan 28;328(4):257-65 [8418407.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4848-50 [8069850.001]
  • [Cites] J Exp Med. 1994 Oct 1;180(4):1415-25 [7931074.001]
  • [Cites] Genet Res. 1994 Oct;64(2):99-106 [7813906.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):290-3 [7882795.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):385-8 [9247277.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 1):E740-7 [9814991.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):57-82 [15765919.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):752-3 [15944689.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] FASEB J. 2005 Dec;19(14):2005-7 [16223785.001]
  • [Cites] J Submicrosc Cytol Pathol. 2005 Aug;37(2):109-204 [16335592.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):197-202 [16337739.001]
  • [Cites] Lung Cancer. 2000 Jan;27(1):27-35 [10672781.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6166-73 [10843666.001]
  • [Cites] Eur Respir J. 2000 Jun;15(6):1087-93 [10885428.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2237-42 [11080091.001]
  • [Cites] Curr Opin Immunol. 2000 Dec;12(6):624-31 [11102764.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Jan;280(1):E75-82 [11120661.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • (PMID = 17255336.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA033497; United States / NCI NIH HHS / CA / R01 CA096133; United States / NCI NIH HHS / CA / CA33497; United States / NCI NIH HHS / CA / CA96133
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinogens; 3IN71E75Z5 / Urethane; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, mouse
  • [Other-IDs] NLM/ PMC1851863
  •  go-up   go-down


87. Su MY, Hsu CM, Ho YP, Chen PC, Lin CJ, Chiu CT: Comparative study of conventional colonoscopy, chromoendoscopy, and narrow-band imaging systems in differential diagnosis of neoplastic and nonneoplastic colonic polyps. Am J Gastroenterol; 2006 Dec;101(12):2711-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 110 colorectal polyps, 65 were adenomas, 40 were hyperplastic polyps, and five were adenocarcinomas.
  • For differential diagnosis of neoplastic (adenoma and adenocarcinoma) and nonneoplastic (hyperplastic) polyps, the sensitivity of the conventional colonoscope for detecting neoplastic polyps was 82.9%, specificity was 80.0% and diagnostic accuracy was 81.8%, significantly lower than those achieved with the NBI system (sensitivity 95.7%, specificity 87.5%, accuracy 92.7%) and chromoendoscopy (sensitivity 95.7%, specificity 87.5%, accuracy 92.7%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Coloring Agents. Diagnosis, Differential. Feasibility Studies. Female. Humans. Indigo Carmine. Male. Middle Aged. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. INDIGO .
  • Hazardous Substances Data Bank. Indigotindisulfonate sodium .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2007 Jun;102(6):1326; author reply 1327 [17531017.001]
  • [CommentIn] Am J Gastroenterol. 2006 Dec;101(12):2717-8 [17227518.001]
  • (PMID = 17227517.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; D3741U8K7L / Indigo Carmine
  •  go-up   go-down


88. Diehl D, Oesterle D, Elmlinger MW, Hoeflich A, Wolf E, Lahm H: IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment. J Carcinog; 2006;5:24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant crypt foci (ACF) served as markers of early lesions in the colonic mucosa, whereas adenomas and carcinomas characterized the endpoints of tumor development.
  • Nevertheless, adenomas and adenocarcinomas of the colon, present after 34 weeks in both genetic groups, were not found at different frequency.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21092-8 [12657632.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4368-74 [12907606.001]
  • [Cites] Lancet. 1992 Sep 12;340(8820):626-30 [1355210.001]
  • [Cites] Cell Struct Funct. 2003 Aug;28(4):255-63 [14586135.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):862-6 [14624779.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2642-9 [14669304.001]
  • [Cites] Carcinogenesis. 2004 Apr;25(4):527-33 [14688025.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1600-3 [14996716.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Apr;288(4):F703-13 [15572521.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1564-7 [1997197.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1236-40 [2917353.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6187-92 [3167865.001]
  • [Cites] Endocrinology. 1994 Nov;135(5):1877-86 [7525257.001]
  • [Cites] Exp Cell Res. 1995 Feb;216(2):342-51 [7531153.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] J Pathol. 1995 May;176(1):37-44 [7616355.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3141-53 [15735679.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1819-22 [16030122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15593-8 [16230630.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):561-71 [16375662.001]
  • [Cites] Hum Pathol. 1991 Mar;22(3):287-94 [1706308.001]
  • [Cites] Carcinogenesis. 1991 Nov;12(11):2093-8 [1934294.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):624-30 [1991846.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):452-9 [8050827.001]
  • [Cites] Mutagenesis. 1996 May;11(3):241-5 [8671746.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):781-90 [9797687.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1276-80 [9809551.001]
  • [Cites] Carcinogenesis. 1999 Mar;20(3):509-13 [10190570.001]
  • [Cites] Gut. 1999 May;44(5):704-8 [10205209.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3278-88 [10207053.001]
  • [Cites] Immunol Cell Biol. 1999 Jun;77(3):256-62 [10361258.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):15-7 [10449601.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1070-6 [10706126.001]
  • [Cites] Cell Prolif. 2000 Feb;33(1):1-18 [10741640.001]
  • [Cites] Toxicol Lett. 2000 Jun 5;115(3):205-12 [10814890.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1117-20 [10836998.001]
  • [Cites] Growth Horm IGF Res. 1998 Jun;8(3):185-93 [10984306.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1344-50 [11044360.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):1935-40 [11062151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):901-5 [12223436.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38239-44 [12154096.001]
  • [Cites] Growth Horm IGF Res. 2002 Feb;12(1):69-79 [12127304.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7318-24 [11585772.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):315-20 [11181454.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):317-21 [11377291.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4942-50 [11526479.001]
  • (PMID = 17118177.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660565
  •  go-up   go-down


89. Scherübl H: Rectal carcinoids are on the rise: early detection by screening endoscopy. Endoscopy; 2009 Feb;41(2):162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, endoscopic screening of the colorectum is effective in the early diagnosis not only of colorectal adenomas and adenocarcinomas but also of carcinoids.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19214898.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 26
  •  go-up   go-down


90. Götz R: Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression. Cancer Cell Int; 2008;8:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutational activation of protein kinases and loss of cell adhesion occur together in human lung adenocarcinoma but how these two pathways interconnect is only poorly understood.
  • Mouse models of human lung adenocarcinoma with oncogene expression targeted to subtypes of lung epithelial cells led to formation of adenomas or adenocarcinomas that lacked metastatic potential.
  • Conditional genetic abrogation of epithelial tumour cell adhesion in mice with benign lung tumours induced by oncogenic RAF kinase has been demonstrated to induce intratumourous vascularization (angiogenic switch), progression to invasive adenocarcinoma and micrometastasis.

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5671-81 [8065304.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1858-62 [8127895.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Dev Biol. 1993 Apr;156(2):426-43 [8462742.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):883-9 [8806677.001]
  • [Cites] Histol Histopathol. 1996 Apr;11(2):463-83 [8861769.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1521-6 [9118033.001]
  • [Cites] Cell. 1997 Sep 5;90(5):871-82 [9298899.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6166-70 [9497337.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1021-6 [9500465.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):5762-70 [9742093.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):687-99 [10037790.001]
  • [Cites] J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45 [10085258.001]
  • [Cites] Dev Biol. 1999 May 1;209(1):60-71 [10208743.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 2;261(2):406-11 [10425198.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36734-40 [10593980.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11858-64 [10766812.001]
  • [Cites] Cell Growth Differ. 2000 Apr;11(4):185-90 [10775035.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2501-14 [11018017.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):316-21 [11170292.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):813-8 [11259097.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20436-43 [11279024.001]
  • [Cites] Cell. 2001 May 4;105(3):391-402 [11348595.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):768-76 [16084946.001]
  • [Cites] PLoS Med. 2005 Nov;2(11):e313 [16187797.001]
  • [Cites] Curr Biol. 2005 Nov 22;15(22):1989-97 [16303557.001]
  • [Cites] Cell. 2005 Dec 2;123(5):889-901 [16325582.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):729-39 [16332724.001]
  • [Cites] Immunity. 2005 Dec;23(6):599-609 [16356858.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2279-86 [16489032.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Genome Res. 2006 May;16(5):595-605 [16606705.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):606-13 [16699315.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Development. 2006 Jul;133(13):2455-65 [16735479.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2261-71 [16894562.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1048-56 [16951689.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):846-56 [17060944.001]
  • [Cites] Methods Enzymol. 2006;419:285-321 [17141060.001]
  • [Cites] Genes Dev. 2007 Feb 15;21(4):379-84 [17299132.001]
  • [Cites] Cell. 2007 Feb 23;128(4):735-45 [17320510.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):369-78 [17377526.001]
  • [Cites] Nat Rev Genet. 2007 May;8(5):341-52 [17440531.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1006-13 [17459054.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4933-9 [17510423.001]
  • [Cites] Cell. 2007 Jun 1;129(5):957-68 [17540175.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):318-24 [17554336.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):445-51 [17597761.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):260-2 [17637646.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Arch Toxicol. 1991;65(2):81-94 [1711838.001]
  • [Cites] Exp Cell Res. 1967 Apr;46(1):144-54 [6025276.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):461-71 [7542250.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4553-61 [7623846.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Mar 28;208(3):1067-72 [7702605.001]
  • [Cites] Cell Adhes Commun. 1994 Aug;2(4):319-27 [7820535.001]
  • [Cites] J Cell Biol. 1994 Dec;127(5):1375-80 [7962096.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Nov 30;205(1):73-8 [7999105.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5023-7 [17311002.001]
  • [Cites] Cell Biol Int. 2007 Apr;31(4):366-73 [17336101.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):676-9 [17377531.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3113-21 [17496910.001]
  • [Cites] J Pathol. 2007 Jul;212(3):287-94 [17534846.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):313-7 [17554338.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):145-59 [17692806.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):101-6 [18059259.001]
  • [Cites] Cancer Metastasis Rev. 2008 Jun;27(2):147-58 [18246411.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):547-53 [11709274.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Mech Dev. 2002 Jul;115(1-2):53-62 [12049767.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):173-82 [12107102.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6297-303 [12414660.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1333-8 [12423687.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):97S-104S [12527569.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2287-97 [12640114.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2268-77 [12727849.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):118-32 [14964308.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] J Cell Sci. 2004 Jul 1;117(Pt 15):3207-19 [15226396.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):339-49 [15492040.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85 [15520807.001]
  • [Cites] APMIS. 2005 Jan;113(1):54-7 [15676015.001]
  • [Cites] Development. 2005 Mar;132(6):1363-74 [15716345.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):1-10 [15837535.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):45-51 [18196970.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):55-70 [18371336.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Annu Rev Physiol. 2004;66:601-23 [14977415.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] J Biol. 2004;3(3):11 [15186480.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2225-30 [15371335.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Trends Cell Biol. 2004 Nov;14(11):639-47 [15519853.001]
  • [Cites] Cell Res. 2005 Jan;15(1):28-32 [15686623.001]
  • [Cites] EMBO J. 2005 Apr 20;24(8):1571-83 [15791206.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9719-26 [16266992.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Cell. 2005 Dec 2;123(5):903-15 [16325583.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):283-9 [16397241.001]
  • [Cites] Genes Dev. 2006 Feb 15;20(4):399-410 [16481469.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1111-5 [16564000.001]
  • [Cites] Development. 2006 May;133(9):1611-24 [16613830.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1496-510 [16705038.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1394-404 [16751178.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62 [17052169.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • (PMID = 18492263.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2427011
  •  go-up   go-down


96. Bakaris S, Cetinkaya A, Ezberci F, Ekerbicer H: Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma. Histol Histopathol; 2008 Sep;23(9):1043-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.
  • When compared to the intensity observed in adjacent normal mucosal epithelial cells, strong nuclear staining for CDX2 was observed in 10 (100%) of 10 colonic adenomas, 30 (88.2%) of 34 colorectal adenocarcinomas, including 17(94.47%) of 18 well-or moderately differentiated tumors and 13(81.2%) of 16 high-grade tumors.
  • The percentage of CDX2 immunopositive cells was generally lower in carcinomas than in adenomas (p<0.001) and lower in moderately or poorly differentiated tumors than in well-differentiated tumors (p<0.001).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Homeodomain Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581275.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


97. Sparr JA, Bandipalliam P, Redston MS, Syngal S: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol; 2009 Feb;33(2):309-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phenotypic manifestations of Lynch syndrome in this patient included multiple adenomas and adenocarcinomas of the colon and also several other Lynch syndrome-associated cancers.
  • The patient's adenocarcinoma of the colon and IPMN of the pancreas showed identical immunohistochemical staining profiles with loss of expression of MSH2 and MSH6 proteins and high levels of microsatellite instability.
  • The immunohistochemical staining and microsatellite instability patterns of the adenocarcinoma of the colon and IPMN gives strong evidence to support the consideration of IPMN as part of the spectrum of lesions found in Lynch syndrome.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):444-9 [18398828.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):537-42 [12808058.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):235-8 [14760534.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • (PMID = 18987546.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K24 CA113433-04; United States / PHS HHS / / K24-113433
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ NIHMS77744; NLM/ PMC2631097
  •  go-up   go-down


98. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H: The Intestinal Wnt/TCF Signature. Gastroenterology; 2007 Feb;132(2):628-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Independently, differential gene-expression profiles of human adenomas and adenocarcinomas vs normal colonic epithelium were obtained.
  • RESULTS: Expression analyses of approximately 80 genes common between these data sets were performed in a murine adenoma model.
  • CONCLUSIONS: The genes were invariably expressed in adenomas, yet could be subdivided into 3 modules, based on expression in distinct crypt compartments.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Animals. Cell Line, Tumor. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Gene Expression Profiling. Humans. Mice. Oligonucleotide Array Sequence Analysis. Paneth Cells / metabolism. RNA, Messenger / metabolism. T Cell Transcription Factor 1 / metabolism. Time Factors. Transcription Factor 7-Like 2 Protein. Transfection. beta Catenin / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320548.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / T Cell Transcription Factor 1; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Tcf7l2 protein, mouse; 0 / Transcription Factor 7-Like 2 Protein; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


99. Schittenhelm J, Psaras T, Meyermann R, Honegger J, Beschorner R: Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. Folia Neuropathol; 2010;48(2):75-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms.
  • OBJECTIVES: Previous studies have shown an inverse correlation between the expression of CDX2 (also known as CDX3) and tumour grade, stage and lymph node dissemination in colorectal adenomas and adenocarcinomas.
  • Furthermore, only very few data are available on CDX2 expression in normal pituitary gland tissue and/or pituitary adenomas.
  • MATERIAL AND METHODS: We investigated CDX2 expression in 28 normal pituitary glands, 75 pituitary adenomas of varying hormonal activity (including 7 invasive adenomas and 7 atypical adenomas) and 23 craniopharyngiomas (17 adamantinous and 6 papillary) in tissue microarrays.
  • RESULTS: None of the pituitary adenomas, craniopharyngiomas and normal pituitary glands showed expression of CDX2.
  • CONCLUSIONS: There is no evidence for that CDX2 might play a role in tumourigenesis, invasive growth or tumour recurrence of pituitary adenomas or in tumourigenesis of craniopharyngiomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20602288.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


100. Cody DD, Nelson CL, Bradley WM, Wislez M, Juroske D, Price RE, Zhou X, Bekele BN, Kurie JM: Murine lung tumor measurement using respiratory-gated micro-computed tomography. Invest Radiol; 2005 May;40(5):263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The authors used K-ras mice, which develop lung adenomas and adenocarcinomas through somatic activation of the K-ras oncogene.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenoma / pathology. Adenoma / radiography. Animals. Disease Models, Animal. Female. Male. Mice. Mice, Transgenic. Pilot Projects. Radiographic Image Enhancement. Reproducibility of Results. Respiration

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829823.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / R01 CA80686; United States / NCI NIH HHS / CA / U01 CA84306
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement